Product,EMA,FDA,EN,Other,WHO,Year,Generic,DrugBank ID,ATC,ChEMBL,Indications,Targets,Last Update,SMILES,MolWeight,LogP,NumHDonors,NumHAcceptors,SMILES_cleaned,MetaText
Abemaciclib,Y,Y,N,,N,2017.0,N,DB12001,L01EF03,CHEMBL3301610,Advanced Breast Cancer; Metastatic Breast Cancer,CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA,2024-07-24,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,506.6050000000003,4.936920000000004,1,8,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA>
Abiraterone,Y,Y,N,,Y,2011.0,Y,DB05812,L02BX03,CHEMBL254328,Metastatic Castration Resistant Prostate Cancer,CYP17A1; CPB2; AR; YBX1; TP53; PTEN; SRD5A2; APC; SRD5A1; TSPYL1; SRD5A3; DSE,2024-07-25,CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O,349.51800000000003,5.398600000000006,1,2,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,<INDICATION=Metastatic Castration Resistant Prostate Cancer> <TARGET=CYP17A1; CPB2; AR; YBX1; TP53; PTEN; SRD5A2; APC; SRD5A1; TSPYL1; SRD5A3; DSE>
Acalabrutinib,Y,Y,N,,N,2017.0,N,DB11703,L01EL02,CHEMBL3707348,Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma,EPHB3; FGR; EPHA8; EPHX2; EEGV1; EN1; ENO2; EFNA1; EPS15; DXO; ERBB4; TP53; CYP3A4; BTK; TEC; EFNB2; MS4A2,2024-07-24,CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5,465.51700000000017,3.3126000000000015,2,7,CC#CC(=O)N1CCCC1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma> <TARGET=EPHB3; FGR; EPHA8; EPHX2; EEGV1; EN1; ENO2; EFNA1; EPS15; DXO; ERBB4; TP53; CYP3A4; BTK; TEC; EFNB2; MS4A2>
Aclarubicin,N,N,N,Japan,N,,,DB11617,L01DB04,CHEMBL502620,,TOP2A; SMN1; CSF2,2024-07-24,CCC1(CC(C2=C(C3=C(C=C2C1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O,811.878,3.1577000000000006,4,16,CCC1(O)CC(OC2CC(N(C)C)C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)C1C(=O)OC,<INDICATION=nan> <TARGET=TOP2A; SMN1; CSF2>
Adagrasib,N,Y,N,,N,2022.0,N,DB15568,L01XX77,CHEMBL4594350,"Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer",KRAS; GPM6B,2024-07-24,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,604.1300000000001,4.732980000000005,0,8,C=C(F)C(=O)N1CCN(c2nc(OCC3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)CC1CC#N,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; GPM6B>"
Afatinib,Y,Y,N,,Y,2013.0,N,DB08916,L01EB03,CHEMBL1173655,"Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer",NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO,2024-07-24,CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,485.94700000000023,4.389900000000003,2,7,CN(C)CC=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1,"<INDICATION=Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer> <TARGET=NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO>"
Alectinib,Y,Y,N,,N,2015.0,N,DB11363,L01ED03,CHEMBL1738797,"Refractory, metastatic Non small cell lung cancer",RET; ALK; ROS1; EML4; TP53; CYP3A4; IDH2; HBEGF; DRD4; BRAF,2024-07-24,CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C,482.6280000000002,4.773280000000004,1,5,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=RET; ALK; ROS1; EML4; TP53; CYP3A4; IDH2; HBEGF; DRD4; BRAF>"
Alitretinoin,Y,Y,N,,N,1999.0,N,DB00523,D11AH04; L01XF02,CHEMBL705,AIDS-related Kaposi's Sarcoma,RARB; RXRA; RARG; SFTPA1; RXRG; HCN2; RARA; RXRB; ERBB2; BCHE; EHMT2; BCHEL3; GCK; CGA; SERPINE1; CCR2; CD34; BCHEL1; P2RY2; CETP; VDR,2024-07-24,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,300.44200000000006,5.602600000000005,1,1,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,<INDICATION=AIDS-related Kaposi's Sarcoma> <TARGET=RARB; RXRA; RARG; SFTPA1; RXRG; HCN2; RARA; RXRB; ERBB2; BCHE; EHMT2; BCHEL3; GCK; CGA; SERPINE1; CCR2; CD34; BCHEL1; P2RY2; CETP; VDR>
Alpelisib,Y,Y,N,,N,2019.0,N,DB12015,L01EM03,CHEMBL2396661,Advanced Metastatic Breast Cancer,F5; PIK3CB; PIK3CG; BRAF; SGK1; CDK4; PIK3CA; PIK3CD; PIK3R2; PIK3C2A; ERBB2; ESR1; FGFR2; PIK3R1; PI4KA; PIK3R4; F7R; MAP2K1; ESR2; PTEN; FGFR3; PIK3C2B; TP53; PIK3R5; PIK3R6; PIK3R3; FGFR1; PIK3C2G; F7; NRAS; MTOR; ARID1A; PIK3C3; RB1; HRAS,2024-07-24,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,441.4790000000001,3.835020000000002,2,5,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,<INDICATION=Advanced Metastatic Breast Cancer> <TARGET=F5; PIK3CB; PIK3CG; BRAF; SGK1; CDK4; PIK3CA; PIK3CD; PIK3R2; PIK3C2A; ERBB2; ESR1; FGFR2; PIK3R1; PI4KA; PIK3R4; F7R; MAP2K1; ESR2; PTEN; FGFR3; PIK3C2B; TP53; PIK3R5; PIK3R6; PIK3R3; FGFR1; PIK3C2G; F7; NRAS; MTOR; ARID1A; PIK3C3; RB1; HRAS>
Altretamine,N,N,Y,,N,1990.0,N,DB00488,L01XX03,CHEMBL1455,Ovarian Cancer; Ovarian Cancer Stage III,CYP1A2,2024-02-07,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,210.285,0.0696000000000001,0,6,CN(C)c1nc(N(C)C)nc(N(C)C)n1,<INDICATION=Ovarian Cancer; Ovarian Cancer Stage III> <TARGET=CYP1A2>
Aminolevulinic Acid,Y,Y,N,,N,1999.0,N,DB00855,L01XD04,CHEMBL601,Basal Cell Carcinoma (BCC); Squamous Cell Carcinoma (SCC),BCL2,2024-02-07,C(CC(=O)O)C(=O)CN,131.13099999999997,-0.621,2,3,NCC(=O)CCC(=O)O,<INDICATION=Basal Cell Carcinoma (BCC); Squamous Cell Carcinoma (SCC)> <TARGET=BCL2>
Amrubicin,N,N,N,Japan,N,2002.0,,DB06263,L01DB10,CHEMBL1186894,,TOP2A,2024-02-07,CC(=O)C1(CC(C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)OC5CC(C(CO5)O)O)N,483.47300000000024,0.6317999999999998,5,10,CC(=O)C1(N)Cc2c(O)c3c(c(O)c2C(OC2CC(O)C(O)CO2)C1)C(=O)c1ccccc1C3=O,<INDICATION=nan> <TARGET=TOP2A>
Amsacrine,N,N,N,,N,1987.0,N,DB00276,L01XX01,CHEMBL43,"Leukemia, Acute; Refractory Leukemia",TOP2A; CYP2C9; TOP2B; CBX1; CYP3A4; EHMT2; ATXN2; CYP2C19; HSD17B10; MTOR; CYP2D6; ATAD5; BTF3P11; DRD1; CYP1A2,2024-07-24,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42,393.4680000000001,4.511700000000003,2,5,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,"<INDICATION=Leukemia, Acute; Refractory Leukemia> <TARGET=TOP2A; CYP2C9; TOP2B; CBX1; CYP3A4; EHMT2; ATXN2; CYP2C19; HSD17B10; MTOR; CYP2D6; ATAD5; BTF3P11; DRD1; CYP1A2>"
Anastrozole,N,Y,Y,,Y,1995.0,Y,DB01217,L02BG03,CHEMBL1399,"Advanced Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer; Invasive, early Breast Cancer",ESR1; IGF2; PGR; CYP19A1; TUBB1; DLG2; MAP4K4; CLDN11; CSMD1; ERBB2; ZNF613; CYP1B1; CPD,2024-07-24,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,293.374,2.928760000000002,0,5,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,"<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer; Invasive, early Breast Cancer> <TARGET=ESR1; IGF2; PGR; CYP19A1; TUBB1; DLG2; MAP4K4; CLDN11; CSMD1; ERBB2; ZNF613; CYP1B1; CPD>"
Apalutamide,Y,Y,N,,N,2018.0,N,DB11901,L02BB05,CHEMBL3183409,Nonmetastatic Prostate Cancer,AR; BEVI,2024-07-24,CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F,477.4430000000002,3.5315800000000026,1,5,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,<INDICATION=Nonmetastatic Prostate Cancer> <TARGET=AR; BEVI>
Arsenic Trioxide,Y,Y,N,,Y,2018.0,Y,DB01169,L01XX27,CHEMBL1200978,Refractory Acute Promyelocytic Leukemia,RARA; SMO; IL6; BIRC5; BDNF; CCND1; TXNRD1; FGFR1; MYCN; SERPINE1; IKBKB; HSPA4; PML; JUN; FLT3; MAPK3; EPO; TERT; FAS; GSTO1; CDKN1A; DNMT1; MT1A; MAPK10; TXNRD2; MAPK1,2024-07-25,[O-2].[O-2].[O-2].[As+3].[As+3],197.841,-1.118,0,0,[As+3].[As+3].[O-2].[O-2].[O-2],<INDICATION=Refractory Acute Promyelocytic Leukemia> <TARGET=RARA; SMO; IL6; BIRC5; BDNF; CCND1; TXNRD1; FGFR1; MYCN; SERPINE1; IKBKB; HSPA4; PML; JUN; FLT3; MAPK3; EPO; TERT; FAS; GSTO1; CDKN1A; DNMT1; MT1A; MAPK10; TXNRD2; MAPK1>
Asciminib,Y,Y,N,,N,2021.0,N,DB12597,L01EA06,CHEMBL4208229,Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase,ABL1; BCR,2024-07-24,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,449.845,3.462900000000001,3,6,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CCC(O)C2)c(-c2ccn[nH]2)c1,<INDICATION=Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase> <TARGET=ABL1; BCR>
Avapritinib,Y,Y,N,,N,2020.0,N,DB15233,L01EX18,CHEMBL4204794,Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor,KIT; PDGFRA; FLT3; DPT; CBL,2024-07-24,CC(C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N,498.5700000000003,2.6077000000000004,1,10,Cn1cc(-c2cc3c(N4CCN(c5ncc(C(C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,<INDICATION=Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=KIT; PDGFRA; FLT3; DPT; CBL>
Axitinib,Y,Y,N,,N,2012.0,N,DB06626,L01EK01,CHEMBL1289926,Advanced Thyroid cancer,KDR; ABCG2; YES1; FLT1; UGT1A9; UGT1A10; DRD2; PDGFRB; PDGFRA; TP53; VHL; ABL1; FABP5; KIT; CD274; PDGFB; HIF1A; UGT1A7; UGT1A8; BRAF; OR2B11; FLT4,2024-07-24,CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4,386.48,4.6391000000000036,2,4,CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1,<INDICATION=Advanced Thyroid cancer> <TARGET=KDR; ABCG2; YES1; FLT1; UGT1A9; UGT1A10; DRD2; PDGFRB; PDGFRA; TP53; VHL; ABL1; FABP5; KIT; CD274; PDGFB; HIF1A; UGT1A7; UGT1A8; BRAF; OR2B11; FLT4>
Azacitidine,Y,Y,N,,N,2004.0,Y,DB00928,L01BC07,CHEMBL1489,Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia,NRAS; DNMT1; TG; MTHFR; ALDH1A1; GMNN; NFE2L2; IDH1; SMAD3; XRCC1; KRAS; TAGLN; FLT3; ATAD5; AFP; GGT1; MYC; ABL1; CDA; MGMT; TP53; AR; IDH2; NR3C1; THPO; LIF; HTT; PLAU; PTPN11; DNMT3A; TYMS; CBL; HBB; GSTP1; CD247; RORC; TRIT1; GATA2; TET2; IL11,2024-07-25,C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,244.207,-3.167999999999999,4,9,Nc1ncn(C2OC(CO)C(O)C2O)c(=O)n1,<INDICATION=Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia> <TARGET=NRAS; DNMT1; TG; MTHFR; ALDH1A1; GMNN; NFE2L2; IDH1; SMAD3; XRCC1; KRAS; TAGLN; FLT3; ATAD5; AFP; GGT1; MYC; ABL1; CDA; MGMT; TP53; AR; IDH2; NR3C1; THPO; LIF; HTT; PLAU; PTPN11; DNMT3A; TYMS; CBL; HBB; GSTP1; CD247; RORC; TRIT1; GATA2; TET2; IL11>
Belinostat,N,Y,N,,N,2014.0,N,DB05015,L01XH04,CHEMBL408513,Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified,UGT1A1; HDAC3; HDAC9; HDAC6; HDAC5; HDAC10; HDAC1; FBXW7; HDAC7; GARS1; KMT2A; GAPDHP1; HDAC11; GART; MSTN; GAS1; GDF9; GAS2; GDF2; HDAC4; HDAC8; HDAC2,2024-07-24,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,318.35400000000004,2.006,3,4,O=C(C=Cc1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,<INDICATION=Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified> <TARGET=UGT1A1; HDAC3; HDAC9; HDAC6; HDAC5; HDAC10; HDAC1; FBXW7; HDAC7; GARS1; KMT2A; GAPDHP1; HDAC11; GART; MSTN; GAS1; GDF9; GAS2; GDF2; HDAC4; HDAC8; HDAC2>
Belotecan,N,N,N,South Korea,N,2003.0,,DB12459,L01CE04,CHEMBL2111084,,TOP1,2024-02-07,CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CCNC(C)C)O,433.50800000000015,2.620100000000001,2,7,CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CCNC(C)C,<INDICATION=nan> <TARGET=TOP1>
Belzutifan,N,Y,N,,N,2023.0,N,DB15463,L01XX74,CHEMBL4585668,Advanced Renal Cell Carcinoma,HMGB2,2024-07-24,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,383.347,3.288880000000002,1,5,CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1C(O)C(F)C2F,<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=HMGB2>
Bendamustine,N,Y,Y,,Y,2008.0,Y,DB06769,L01AA09,CHEMBL487253,Chronic Lymphocytic Leukaemia (CLL); Follicular Non-Hodgkin's Lymphoma Refractory; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia (WM); Recurrent multiple myeloma; Refractory indolent B cell non-hodgkin lymphoma,ATM; TP53; CD69,2024-07-24,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,358.2690000000001,3.2646000000000015,1,4,Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Follicular Non-Hodgkin's Lymphoma Refractory; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia (WM); Recurrent multiple myeloma; Refractory indolent B cell non-hodgkin lymphoma> <TARGET=ATM; TP53; CD69>
Bexarotene,Y,Y,N,,N,1999.0,Y,DB00307,L01XF03,CHEMBL1023,Refractory peripheral cutaneous T-cell lymphoma,NR1I2; OPN1SW; RXRB; RXRG; USP1; HCN2; NR1H3; RXRA; MAPK8; KAT2A; BLM; CCND1,2024-07-24,CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C,348.4860000000002,6.103720000000006,1,1,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,<INDICATION=Refractory peripheral cutaneous T-cell lymphoma> <TARGET=NR1I2; OPN1SW; RXRB; RXRG; USP1; HCN2; NR1H3; RXRA; MAPK8; KAT2A; BLM; CCND1>
Bicalutamide,N,Y,Y,,Y,1995.0,Y,DB01128,L02BB03,CHEMBL409,Stage D2 Prostatic carcinoma,CYP2B6; CFLAR; AR; BAX; VDR; KLK3; CDH1; KMT2D; FST; BEVI,2024-07-25,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,430.3790000000001,2.879580000000002,2,5,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=CYP2B6; CFLAR; AR; BAX; VDR; KLK3; CDH1; KMT2D; FST; BEVI>
Binimetinib,Y,Y,N,,N,2018.0,N,DB11967,L01EE03,CHEMBL3187723,Metastatic Melanoma; Unresectable Melanoma,BRAF; APC; MAP2K1; ATM; HRAS; NRAS; MAP2K7; UGT1A1; NF1; PTEN; PIK3CA; MAP2K3; KRAS; KIT; MAP2K4; NR2F6; JAK2; MAP2K2; MAP2K6; MAP2K5,2024-07-24,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,441.23200000000014,3.0113,3,6,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; APC; MAP2K1; ATM; HRAS; NRAS; MAP2K7; UGT1A1; NF1; PTEN; PIK3CA; MAP2K3; KRAS; KIT; MAP2K4; NR2F6; JAK2; MAP2K2; MAP2K6; MAP2K5>
Bleomycin,N,Y,Y,,Y,1973.0,Y,DB00290,L01DC01,CHEMBL403664,"Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma",CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP,2024-07-24,CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O,1415.5760000000005,-7.703580000000028,20,31,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bortezomib,Y,Y,N,,Y,2003.0,Y,DB00188,L01XG01,CHEMBL325041,Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM),PSMB11; PSMB4; PSMB10; PSMC3; HSPB2; AR; BDNF; PSMC2; PSMA7; PSMD4; PSMD2; PSMD7; PSMA4; B2M; PSME2; PSMB1; PSMC5; PSMD12; PSMA6; PSMB5; PSMA2; HSPA4; PSMD1; PMAIP1; PIK3CA; PSMB2; PSME1; BCL2L2; PSMD9; PSMD14; PSMA5; PSMC1P1; PSMB6; PSMA1; ADRM1; PSME4; PSMC6; PSMD11; PLG; PSMD8; PSMB8; PSMB3; NFE2L2; PSMB9; PSMB7; F12; PSMC1; FGFR3; FLT3; PSMD6; PSMC4; NFKB1; E2F1; PRSS2; PSME2P2; CCND1; PSMD13; PSMF1; CAPN1; DDIT3; FRA6F; PSME3; F2; PSMD10P1; PSMA8; PSMD5; BCL2; PSMD4P1; PSMC3IP; PRSS3; PSMD10; TP53; PRB2; PSMD10P3; CTSB; PIK3CG; PSMA3; PIPSL; PSMD10P2; GATA2; CTSL; PRSS1; SEM1; PLAT; XIAP; PSMD3,2024-07-25,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,384.2450000000001,0.3605999999999987,4,6,CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,<INDICATION=Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM)> <TARGET=PSMB11; PSMB4; PSMB10; PSMC3; HSPB2; AR; BDNF; PSMC2; PSMA7; PSMD4; PSMD2; PSMD7; PSMA4; B2M; PSME2; PSMB1; PSMC5; PSMD12; PSMA6; PSMB5; PSMA2; HSPA4; PSMD1; PMAIP1; PIK3CA; PSMB2; PSME1; BCL2L2; PSMD9; PSMD14; PSMA5; PSMC1P1; PSMB6; PSMA1; ADRM1; PSME4; PSMC6; PSMD11; PLG; PSMD8; PSMB8; PSMB3; NFE2L2; PSMB9; PSMB7; F12; PSMC1; FGFR3; FLT3; PSMD6; PSMC4; NFKB1; E2F1; PRSS2; PSME2P2; CCND1; PSMD13; PSMF1; CAPN1; DDIT3; FRA6F; PSME3; F2; PSMD10P1; PSMA8; PSMD5; BCL2; PSMD4P1; PSMC3IP; PRSS3; PSMD10; TP53; PRB2; PSMD10P3; CTSB; PIK3CG; PSMA3; PIPSL; PSMD10P2; GATA2; CTSL; PRSS1; SEM1; PLAT; XIAP; PSMD3>
Bosutinib,Y,Y,N,,N,2010.0,N,DB06616,L01EA04,CHEMBL288441,"Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia",EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1,2024-07-24,CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC,530.4560000000001,5.190380000000005,1,8,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,"<INDICATION=Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia> <TARGET=EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1>"
Brigatinib,Y,Y,N,,N,2017.0,N,DB12267,L01ED04,CHEMBL3545311,Metastatic Non-Small Cell Lung Cancer,ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1,2024-07-24,CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC,584.1050000000001,5.090000000000004,2,9,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1>
Buserelin,N,N,Y,,N,2017.0,N,DB06719,L02AE01,CHEMBL2110824,Stage D2 Prostatic carcinoma,GNRHR; IGFBP1,2024-02-07,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,1239.4470000000006,-1.669100000000012,15,15,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Busulfan,Y,Y,N,,N,1954.0,Y,DB01008,L01AB01,CHEMBL820,Essential Thrombocythemia (ET); Polycythemia Vera (PV); Chronic Chronic myelogenous leukemia,GSTA1; ADK; ABL1; CYP2C19; ABCC3; MTHFR; THPO; ITGAL; BCR; CYP1A2; GALC; GSTM1; CYP2B6; G6PD; CYP2D6; CYP3A4; GSTP1; CYP2C9; SHBG,2024-07-25,CS(=O)(=O)OCCCCOS(=O)(=O)C,246.306,-0.2809999999999997,0,6,CS(=O)(=O)OCCCCOS(C)(=O)=O,<INDICATION=Essential Thrombocythemia (ET); Polycythemia Vera (PV); Chronic Chronic myelogenous leukemia> <TARGET=GSTA1; ADK; ABL1; CYP2C19; ABCC3; MTHFR; THPO; ITGAL; BCR; CYP1A2; GALC; GSTM1; CYP2B6; G6PD; CYP2D6; CYP3A4; GSTP1; CYP2C9; SHBG>
Cabazitaxel,Y,Y,N,,N,2010.0,N,DB06772,L01CD04,CHEMBL1201748,"Refractory, metastatic hormone-refractory Prostate cancer",TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5,2024-07-24,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC,835.9440000000003,4.5678000000000045,3,14,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabozantinib,Y,Y,N,,N,2012.0,N,DB08875,L01EX07,CHEMBL2105717,"Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer",MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET,2024-07-24,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,501.51400000000024,5.5408000000000035,2,6,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,"<INDICATION=Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer> <TARGET=MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET>"
Capecitabine,Y,Y,N,,Y,1998.0,Y,DB01101,L01BC06,CHEMBL1773,"Duke's C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma",MSH2; REV3L; BRAF; SLC22A7; CYP1A1; UPB1; DPYD; PHC1; CD274; GCGR; CCDC77; VPS13D; AREG; TENM4; TMEM131L; CES1P1; ABCG2; TYMS; SLC19A1; CES1; ADGRG7; ZMIZ1; ATM; ANK3; ERBB2; CDX2; PTGS2; TP53; NCOA7; TYMSOS; CCDC70; SPRY2; UGT1A1; CD96; CYP19A1; SELE; LMNTD1; MGAT4A; MIR2054; FAT1; PTEN; MAN1A1; SIRPA; SSU72; DLG5; EXO1; MSH6; MLH1; PPARD; NSUN3; PIK3CA; KRAS; PMS2; SMAD7,2024-07-25,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O,359.35400000000004,0.7602,3,8,CCCCCOC(=O)Nc1nc(=O)n(C2OC(C)C(O)C2O)cc1F,"<INDICATION=Duke's C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma> <TARGET=MSH2; REV3L; BRAF; SLC22A7; CYP1A1; UPB1; DPYD; PHC1; CD274; GCGR; CCDC77; VPS13D; AREG; TENM4; TMEM131L; CES1P1; ABCG2; TYMS; SLC19A1; CES1; ADGRG7; ZMIZ1; ATM; ANK3; ERBB2; CDX2; PTGS2; TP53; NCOA7; TYMSOS; CCDC70; SPRY2; UGT1A1; CD96; CYP19A1; SELE; LMNTD1; MGAT4A; MIR2054; FAT1; PTEN; MAN1A1; SIRPA; SSU72; DLG5; EXO1; MSH6; MLH1; PPARD; NSUN3; PIK3CA; KRAS; PMS2; SMAD7>"
Capivasertib,Y,Y,N,,N,2023.0,N,DB12218,L01EX27,CHEMBL2325741,"Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer",CSTF3; FKBP2; AKT3; AKT2; TP53; ESR1; STK11; PTEN; ERBB2; ESR2; MTOR; CSTP1; PIK3CA; AKT1,2024-07-24,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,428.924,2.1488999999999994,4,6,NC1(C(=O)NC(CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,"<INDICATION=Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer> <TARGET=CSTF3; FKBP2; AKT3; AKT2; TP53; ESR1; STK11; PTEN; ERBB2; ESR2; MTOR; CSTP1; PIK3CA; AKT1>"
Capmatinib,Y,Y,N,,N,2020.0,N,DB11791,L01EX17,CHEMBL3188267,Metastatic Non-Small Cell Lung Cancer,DRD4; MET; PTEN,2024-07-24,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,412.4280000000001,3.429000000000002,1,6,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=DRD4; MET; PTEN>
Carboplatin,N,Y,Y,,Y,1989.0,Y,DB00958,L01XA02,CHEMBL1351,Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin's lymphoma,MUCL3; BIRC5; SCN10A; XRCC1; EGFR; TNF; ADAMTSL4-AS1; ERCC1; BCL2; GCLC; DDX53; PIK3CA; DOCK8; MTHFR; MSH2; MSH6; CD274; RAF1; KRAS; BRCA2; NRG3; HCP5; SLCO1B3; OR4D6; SLC31A1; NR1I2; ERCC2; GSR; ETS2; FGFR1; MLH1; CYP3A5; C6orf15; ATP7A; DSCAM; PPP1R18; ERBB3; TP53; VEGFA; PRRC2A; TRIM5; HLA-C; ATAT1; BRCA1; ALK; EIF4E2; TP73; UGT1A1; PSORS1C1; GSTT1; ATP7B; TIGD1; NF2; GSTP1; POLK; NRAS; MAD1L1; MAP3K1; MSH5; ROS1; MAPT; RNF8; KAT2A; RRM1; PTEN; XYLT2; KEAP1; GPX5; CDSN; HSD17B10; FNTB; NRG1; ALDH1A1; ACSS2; VDR; SLC19A1; ALDH3A1; CDK2; ASS1; SERPINA5; APEX1; CDKN1A; USP1; LIG3; PMS2; ERBB2; SERPINC1; ABCB1,2024-07-24,C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2],371.25,1.7575999999999996,2,2,O=C(O)C1(C(=O)O)CCC1.[NH2-].[NH2-].[Pt+2],<INDICATION=Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin's lymphoma> <TARGET=MUCL3; BIRC5; SCN10A; XRCC1; EGFR; TNF; ADAMTSL4-AS1; ERCC1; BCL2; GCLC; DDX53; PIK3CA; DOCK8; MTHFR; MSH2; MSH6; CD274; RAF1; KRAS; BRCA2; NRG3; HCP5; SLCO1B3; OR4D6; SLC31A1; NR1I2; ERCC2; GSR; ETS2; FGFR1; MLH1; CYP3A5; C6orf15; ATP7A; DSCAM; PPP1R18; ERBB3; TP53; VEGFA; PRRC2A; TRIM5; HLA-C; ATAT1; BRCA1; ALK; EIF4E2; TP73; UGT1A1; PSORS1C1; GSTT1; ATP7B; TIGD1; NF2; GSTP1; POLK; NRAS; MAD1L1; MAP3K1; MSH5; ROS1; MAPT; RNF8; KAT2A; RRM1; PTEN; XYLT2; KEAP1; GPX5; CDSN; HSD17B10; FNTB; NRG1; ALDH1A1; ACSS2; VDR; SLC19A1; ALDH3A1; CDK2; ASS1; SERPINA5; APEX1; CDKN1A; USP1; LIG3; PMS2; ERBB2; SERPINC1; ABCB1>
Carfilzomib,Y,Y,N,,N,2009.0,N,DB08889,L01XG02,CHEMBL451887,Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM),PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5,2024-07-24,CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,719.924,2.5835000000000052,4,8,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carmofur,N,N,N,Japan,N,,,DB09010,L01BC04,CHEMBL460499,,CYP3A4,2024-02-07,CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F,257.265,0.8136999999999999,2,4,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,<INDICATION=nan> <TARGET=CYP3A4>
Carmustine,Y,Y,N,,N,1977.0,Y,DB00262,L01AD01,CHEMBL513,Astrocytomas; Brain Stem Gliomas; Ependymomas; Glioblastomas; Medulloblastomas; Mycosis Fungoides (MF); Recurrent Glioblastoma Multiforme; Refractory Hodgkin Lymphoma; Refractory Multiple Myeloma; Tumors Metastatic to Brain; High grade newly diagnosed Glioma; Refractory Non-Hodgkin's lymphoma,MGMT; ALDH1A1; GSR; CYP2C19; CYP2D6; CYP2C9; PLAU; CYP1A2; G6PD; E2F1; CYP3A4,2024-07-25,C(CCl)NC(=O)N(CCCl)N=O,214.05199999999996,1.157,1,3,O=NN(CCCl)C(=O)NCCCl,<INDICATION=Astrocytomas; Brain Stem Gliomas; Ependymomas; Glioblastomas; Medulloblastomas; Mycosis Fungoides (MF); Recurrent Glioblastoma Multiforme; Refractory Hodgkin Lymphoma; Refractory Multiple Myeloma; Tumors Metastatic to Brain; High grade newly diagnosed Glioma; Refractory Non-Hodgkin's lymphoma> <TARGET=MGMT; ALDH1A1; GSR; CYP2C19; CYP2D6; CYP2C9; PLAU; CYP1A2; G6PD; E2F1; CYP3A4>
Ceritinib,Y,Y,N,,N,2014.0,N,DB09063,L01ED02,CHEMBL2403108,"Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer",ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR,2024-07-24,CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl,558.1480000000001,6.361920000000006,3,8,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,"<INDICATION=Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR>"
Chlorambucil,N,Y,Y,,Y,1957.0,N,DB00291,L01AA02,CHEMBL515,Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Non-Hodgkin's Lymphoma (NHL); Waldenstrom's Macroglobulinemia (WM); Giant follicular lymphoma,ERBB2; GSTM1; TP53; RORC; FANCC; MGMT; GFER; BAZ2B; NFKB1; CXCL12,2024-07-24,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,304.217,3.3779000000000012,1,2,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Non-Hodgkin's Lymphoma (NHL); Waldenstrom's Macroglobulinemia (WM); Giant follicular lymphoma> <TARGET=ERBB2; GSTM1; TP53; RORC; FANCC; MGMT; GFER; BAZ2B; NFKB1; CXCL12>
Cisplatin,N,Y,Y,,Y,1978.0,Y,DB00515,L01XA01,CHEMBL2068237,"Advanced Pancreatic Cancer; Breast Cancer; Cervical Cancers; Esophageal Cancers; Head and Neck Carcinoma; Hepatobiliary Cancers; Hepatoblastomas; Malignant Neoplasm of Stomach; Medulloblastomas; Metastatic Melanoma; Multiple Myeloma (MM); Neuroblastomas; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer Metastatic; Pleural Mesotheliomas; Primary Central Nervous System Lymphoma (PCNSL); Recurrent Endometrial Cancer; Refractory Hodgkin Lymphoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Thymic Cancer; Advanced Bladder cancer; Metastatic Anal cancer; Metastatic Endometrial cancer; Metastatic Penile cancer; Metastatic Testicular cancer; Refractory Non-Hodgkin's lymphoma",CSNK2A3; HEXB; ATM; MLLT3; PPP1R13L; PIK3CA; ERCC4; PLAU; DCBLD1; HMGB1; TPMT; TP53; ERCC1; SYNE3; MECP2; FXN; FGFR1; BAX; ATR; ANPEP; CLCN6; BRCA1; CBX1; BCL2; FANCC; GRP; ERCC6; DFFB; GALNT14; IL6; PRL; GPX5; HPGD; GNAS; TGM2; DDIT3; MGMT; ESR1; MDH2; FASLG; NFE2L2; MPHOSPH8; KDM4E; XIAP; MUTYH; CASP3; CGA; XRCC1; RGS4; TERC; ABCC1; G6PD; CDC25C; GADD45A; ERCC2; FAS; TOP1; KRAS; GSTP1; GSTT1; ATRX; GABPA; GCLM; GCLC; ABCC4; SLC19A1; TYMS; HSD17B10; CYBA; ASS1; LIF; AURKA; ALDH1A1; MTHFD1; FANCA; POLR1G; CD44; MAPT; ALK; ATP7B; EGFR; RB1; SLC22A1; H2AC25; NRAS; APEX1; RECQL; GSTM4; NF2; PPARD; TMEM43; STAT1; OSGEP; GALNT18; DNMT1; BIRC7; MT1H; NR1I2; MAP3K1; RARS1; NHLH1; BRCA2; MDM2; MIR21; EHMT2; IDH1; XRCC3; TP73; SMARCA4; MYCN; CCND1; UBE2I; RAF1; ADH1C; ALOX15; DRAM1; AQP9; HSPA8; ACTL6A; IFNG; E2F1; SEMA6A; KRT20; CDH17; HTR4; MT1F; WFS1; BIRC5; NRG1; RRM1; CHEK1; ABCC5; HSPA4; MSH2; ACSS2; BLMH; CDK12; KAT2A; XRCC5; PTEN; CXCR4; NTRK2; FGFR3; MYC; CD274,2024-07-25,N.N.Cl[Pt]Cl,300.04600000000005,1.7004999999999997,2,2,Cl[Pt]Cl.N.N,"<INDICATION=Advanced Pancreatic Cancer; Breast Cancer; Cervical Cancers; Esophageal Cancers; Head and Neck Carcinoma; Hepatobiliary Cancers; Hepatoblastomas; Malignant Neoplasm of Stomach; Medulloblastomas; Metastatic Melanoma; Multiple Myeloma (MM); Neuroblastomas; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer Metastatic; Pleural Mesotheliomas; Primary Central Nervous System Lymphoma (PCNSL); Recurrent Endometrial Cancer; Refractory Hodgkin Lymphoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Thymic Cancer; Advanced Bladder cancer; Metastatic Anal cancer; Metastatic Endometrial cancer; Metastatic Penile cancer; Metastatic Testicular cancer; Refractory Non-Hodgkin's lymphoma> <TARGET=CSNK2A3; HEXB; ATM; MLLT3; PPP1R13L; PIK3CA; ERCC4; PLAU; DCBLD1; HMGB1; TPMT; TP53; ERCC1; SYNE3; MECP2; FXN; FGFR1; BAX; ATR; ANPEP; CLCN6; BRCA1; CBX1; BCL2; FANCC; GRP; ERCC6; DFFB; GALNT14; IL6; PRL; GPX5; HPGD; GNAS; TGM2; DDIT3; MGMT; ESR1; MDH2; FASLG; NFE2L2; MPHOSPH8; KDM4E; XIAP; MUTYH; CASP3; CGA; XRCC1; RGS4; TERC; ABCC1; G6PD; CDC25C; GADD45A; ERCC2; FAS; TOP1; KRAS; GSTP1; GSTT1; ATRX; GABPA; GCLM; GCLC; ABCC4; SLC19A1; TYMS; HSD17B10; CYBA; ASS1; LIF; AURKA; ALDH1A1; MTHFD1; FANCA; POLR1G; CD44; MAPT; ALK; ATP7B; EGFR; RB1; SLC22A1; H2AC25; NRAS; APEX1; RECQL; GSTM4; NF2; PPARD; TMEM43; STAT1; OSGEP; GALNT18; DNMT1; BIRC7; MT1H; NR1I2; MAP3K1; RARS1; NHLH1; BRCA2; MDM2; MIR21; EHMT2; IDH1; XRCC3; TP73; SMARCA4; MYCN; CCND1; UBE2I; RAF1; ADH1C; ALOX15; DRAM1; AQP9; HSPA8; ACTL6A; IFNG; E2F1; SEMA6A; KRT20; CDH17; HTR4; MT1F; WFS1; BIRC5; NRG1; RRM1; CHEK1; ABCC5; HSPA4; MSH2; ACSS2; BLMH; CDK12; KAT2A; XRCC5; PTEN; CXCR4; NTRK2; FGFR3; MYC; CD274>"
Cladribine,Y,Y,N,,N,1993.0,Y,DB00242,L04AA40; L01BB04,CHEMBL1619,Chronic Lymphocytic Leukaemia (CLL); Cutaneous T-Cell Lymphoma (CTCL); Hairy Cell Leukemia (HCL); Non-Hodgkin's Lymphoma (NHL),DCK; TP53; XIAP; RRM2B; TGFB1; BCL2L2; RRM1; RRM2; CDKN1A; DIABLO; ADA; YES1; IL2RA; NT5C1A; NFE2L2,2024-07-24,C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,285.691,-0.2974000000000001,3,8,Nc1nc(Cl)nc2c1ncn2C1CC(O)C(CO)O1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Cutaneous T-Cell Lymphoma (CTCL); Hairy Cell Leukemia (HCL); Non-Hodgkin's Lymphoma (NHL)> <TARGET=DCK; TP53; XIAP; RRM2B; TGFB1; BCL2L2; RRM1; RRM2; CDKN1A; DIABLO; ADA; YES1; IL2RA; NT5C1A; NFE2L2>
Clofarabine,Y,Y,N,,N,2004.0,Y,DB00631,L01BB06,CHEMBL1750,Acute Lymphoblastic Leukaemia Recurrent; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myelogenous Leukemia (AML); Refractory Langerhans cell histiocytosis,RRM2; AR; POLA1; POLD2; POLA2; FLT3; POLE2; PRIM1; NIPSNAP2; POLD1; APBB1; GBA1LP; RRM2B; POLD3; POLE3; POLE; PRIM2; POLD4; RRM1,2024-07-24,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N,303.68100000000004,-0.3494000000000003,3,8,Nc1nc(Cl)nc2c1ncn2C1OC(CO)C(O)C1F,<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myelogenous Leukemia (AML); Refractory Langerhans cell histiocytosis> <TARGET=RRM2; AR; POLA1; POLD2; POLA2; FLT3; POLE2; PRIM1; NIPSNAP2; POLD1; APBB1; GBA1LP; RRM2B; POLD3; POLE3; POLE; PRIM2; POLD4; RRM1>
Cobimetinib,Y,Y,N,,N,2015.0,N,DB05239,L01EE02,CHEMBL2146883,Metastatic Melanoma; Unresectable Melanoma,BRAF; NRAS; MAP2K2; NR2F6; KRAS; CDKN2A; PIK3CA; MAP2K7; CBL; MAP2K5; MAP2K6; MAP2K4; ERCC2; MAP2K1; NF1; RAF1; MAP2K3; ARAF,2024-07-24,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,531.3160000000001,3.7811000000000026,3,4,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)(C2CCCCN2)C1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; NRAS; MAP2K2; NR2F6; KRAS; CDKN2A; PIK3CA; MAP2K7; CBL; MAP2K5; MAP2K6; MAP2K4; ERCC2; MAP2K1; NF1; RAF1; MAP2K3; ARAF>
Copanlisib,N,Y,N,,N,2017.0,N,DB12483,L01EM02,CHEMBL3218576,Relapsed Follicular Lymphoma,PIK3R2; NRAS; PIK3CG; PIK3R4; PIK3R5; PIK3CD; PIK3CB; PIK3CA; PIK3R3; F7; KIT; PIK3C3; PIK3R6; F7R; PIK3C2A; PTEN; PIK3C2G; AURKB; ETFB; F5; PIK3R1; PIK3C2B,2024-07-24,COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5,480.5290000000004,0.6848000000000003,2,11,COc1c(OCCCN2CCOCC2)ccc2c3n(c(=NC(=O)c4cnc(N)nc4)nc12)CCN3,<INDICATION=Relapsed Follicular Lymphoma> <TARGET=PIK3R2; NRAS; PIK3CG; PIK3R4; PIK3R5; PIK3CD; PIK3CB; PIK3CA; PIK3R3; F7; KIT; PIK3C3; PIK3R6; F7R; PIK3C2A; PTEN; PIK3C2G; AURKB; ETFB; F5; PIK3R1; PIK3C2B>
Crizotinib,Y,Y,N,,N,2011.0,N,DB08865,L01ED01,CHEMBL601719,Metastatic Non-Small Cell Lung Cancer,ROS1; EML4; DRD4; ALK; NPM1; BRAF; MET; ABCB1; KIT; HBEGF; TP53; ERBB2; PIK3CA; JAK2; NTRK1; PTPN12; ABL1; IGF1R; KEAP1; NTRK2; MDM2; KRAS; NTRK3; AREG; HRAS; EGFR,2024-07-24,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,450.3450000000002,5.037700000000004,2,6,CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ROS1; EML4; DRD4; ALK; NPM1; BRAF; MET; ABCB1; KIT; HBEGF; TP53; ERBB2; PIK3CA; JAK2; NTRK1; PTPN12; ABL1; IGF1R; KEAP1; NTRK2; MDM2; KRAS; NTRK3; AREG; HRAS; EGFR>
Cyclophosphamide,N,Y,Y,,Y,1959.0,Y,DB00531,L01AA01,CHEMBL88,"Acute Lymphoblastic Leukaemias (ALL); Acute Myelocytic Leukemia; Adenocarcinoma of the Ovaries; Breast Cancer; Burkitt's Lymphoma; Chronic Lymphocytic Leukaemia (CLL); Chronic Myeloid Leukemia (CML); Disseminated Neuroblastoma; Ewing's Sarcoma; Lung Cancers; Lymphoma, Hodgkins; Multiple Myeloma (MM); Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Waldenstrom's Macroglobulinemia (WM); Advanced Alibert-Bazin syndrome; Histiocytic lymphoma; Metastatic gestational trophoblastic tumor; Mixed-cell type lymphoma; Refractory Small cell lung cancer; Relapsed Wilm's tumor",EHMT2,2024-07-25,C1CNP(=O)(OC1)N(CCCl)CCCl,261.08899999999994,1.884,1,2,O=P1(N(CCCl)CCCl)NCCCO1,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Myelocytic Leukemia; Adenocarcinoma of the Ovaries; Breast Cancer; Burkitt's Lymphoma; Chronic Lymphocytic Leukaemia (CLL); Chronic Myeloid Leukemia (CML); Disseminated Neuroblastoma; Ewing's Sarcoma; Lung Cancers; Lymphoma, Hodgkins; Multiple Myeloma (MM); Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Waldenstrom's Macroglobulinemia (WM); Advanced Alibert-Bazin syndrome; Histiocytic lymphoma; Metastatic gestational trophoblastic tumor; Mixed-cell type lymphoma; Refractory Small cell lung cancer; Relapsed Wilm's tumor> <TARGET=EHMT2>"
Cytarabine,Y,Y,N,,Y,1969.0,Y,DB00987,L01BC01,CHEMBL803,Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Leptomeningeal Metastases; Meningeal leukemia; Non-Hodgkin's Lymphoma (NHL); Blast phase Chronic myelocytic leukemia,ADH1A; IDH2; TP53; CYP3A4; GSTP1; PRIM1; IKZF1; POLA1; HSPA4; KIT; ITGAV; POLD2; GATA3; CCND1; SULT2B1; NQO1; WT1; P2RY12; MSH2; IL1B; EHMT2; TYMSOS; CPT1A; MIR4268; ALK; IGHMBP2; IDH1; CSF2; KMT2A; POLE; NOS3; BIRC5; PRIM2; DOK5; ABCC3; RRM1; CYP2D6; quinone dehydrogenase 2; BMP7; FLT3; TYMS; ATF5; PNPLA3; SLC22A12; NT5C2; POLE2; NRG1; FCGR3A; BRD10; CYP2C9; MIR3117; POLD3; POLA2; SLC29A1; CYP1A2; UGT1A1; VDR; ABCC4; NRAS; RUNX1; RRM2B; POLE3; SLCO1B1; TP73; MED12L; XIAP; FCGR3B; CYP2E1; TPMT; POLD4; NTRK1; CBR3; POLB; MAGEA1; POLD1; NT5C3A; CYP2C19; RRM2; CDA; NCOA3; LINC00251,2024-07-24,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,243.219,-2.562999999999999,4,8,Nc1ccn(C2OC(CO)C(O)C2O)c(=O)n1,<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Leptomeningeal Metastases; Meningeal leukemia; Non-Hodgkin's Lymphoma (NHL); Blast phase Chronic myelocytic leukemia> <TARGET=ADH1A; IDH2; TP53; CYP3A4; GSTP1; PRIM1; IKZF1; POLA1; HSPA4; KIT; ITGAV; POLD2; GATA3; CCND1; SULT2B1; NQO1; WT1; P2RY12; MSH2; IL1B; EHMT2; TYMSOS; CPT1A; MIR4268; ALK; IGHMBP2; IDH1; CSF2; KMT2A; POLE; NOS3; BIRC5; PRIM2; DOK5; ABCC3; RRM1; CYP2D6; quinone dehydrogenase 2; BMP7; FLT3; TYMS; ATF5; PNPLA3; SLC22A12; NT5C2; POLE2; NRG1; FCGR3A; BRD10; CYP2C9; MIR3117; POLD3; POLA2; SLC29A1; CYP1A2; UGT1A1; VDR; ABCC4; NRAS; RUNX1; RRM2B; POLE3; SLCO1B1; TP73; MED12L; XIAP; FCGR3B; CYP2E1; TPMT; POLD4; NTRK1; CBR3; POLB; MAGEA1; POLD1; NT5C3A; CYP2C19; RRM2; CDA; NCOA3; LINC00251>
Dabrafenib,Y,Y,N,,N,2013.0,N,DB08912,L01EC02,CHEMBL2028663,Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation,NRAS; MAP2K4; MAP2K2; MITF; ALK; HLA-DRB1; HRAS; MAP2K6; PIK3CA; CDKN2A; MAP2K1; G6PD; ATXN1L; EFNA2; AKT1; NF1; RAC1; KRAS; CD274; EML4; MAP2K3; TP53; MAP2K5; MAP2K7; PTEN; BRAF; EZH2,2024-07-24,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,519.5740000000002,5.364900000000002,2,7,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=NRAS; MAP2K4; MAP2K2; MITF; ALK; HLA-DRB1; HRAS; MAP2K6; PIK3CA; CDKN2A; MAP2K1; G6PD; ATXN1L; EFNA2; AKT1; NF1; RAC1; KRAS; CD274; EML4; MAP2K3; TP53; MAP2K5; MAP2K7; PTEN; BRAF; EZH2>
Dacarbazine,N,Y,Y,,Y,1975.0,Y,DB00851,L01AX04,CHEMBL476,"Advanced Soft Tissue Sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Pheochromocytomas; Advanced Medullary thyroid cancer; Advanced Pancreatic neuroendocrine tumor",ADK; CYP2C19; CYP1A2; CYP2D6; FN1; CYP2C9; POLA2; MGMT; BAX; CYP1A1; CYP3A4; GSTM1; EPM2AIP1; CXCL8; PLAU,2024-07-25,CN(C)N=NC1=C(NC=N1)C(=O)N,182.18699999999995,0.0689000000000001,2,4,CN(C)N=Nc1nc[nH]c1C(N)=O,"<INDICATION=Advanced Soft Tissue Sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Pheochromocytomas; Advanced Medullary thyroid cancer; Advanced Pancreatic neuroendocrine tumor> <TARGET=ADK; CYP2C19; CYP1A2; CYP2D6; FN1; CYP2C9; POLA2; MGMT; BAX; CYP1A1; CYP3A4; GSTM1; EPM2AIP1; CXCL8; PLAU>"
Dacomitinib,Y,Y,N,,N,2018.0,N,DB11963,L01EB07,CHEMBL2110732,Metastatic Non-Small Cell Lung Cancer,ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2,2024-07-24,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4,469.9480000000003,5.155100000000003,2,6,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=CCN1CCCCC1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2>
Dactinomycin,N,Y,N,,Y,1964.0,Y,DB00970,L01DA01,CHEMBL1554,"Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer",CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT,2024-07-24,CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC6=O)C(C)C)C)C)C(C)C)C)N)C,1255.4379999999985,0.7256400000000024,5,18,Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O,"<INDICATION=Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer> <TARGET=CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT>"
Darolutamide,Y,Y,N,,N,2019.0,N,DB12941,L02BB06,CHEMBL4297185,Non-mestatatic castrate-resistant prostate cancer,AR; BEVI,2024-07-24,CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O,398.8540000000001,2.670080000000001,3,6,CC(Cn1ccc(-c2ccc(C#N)c(Cl)c2)n1)NC(=O)c1cc(C(C)O)[nH]n1,<INDICATION=Non-mestatatic castrate-resistant prostate cancer> <TARGET=AR; BEVI>
Dasatinib,Y,Y,N,,Y,2006.0,Y,DB01254,L01EA02,CHEMBL1421,Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML),TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3,2024-07-24,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,488.01700000000034,3.313540000000002,3,9,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML)> <TARGET=TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3>
Daunorubicin,N,Y,Y,,Y,1979.0,Y,DB00694,L01DB02,CHEMBL178,Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia,MTHFR; SLC22A7; SLC22A17; TOP2B; KMT2A; MIR4268; IGHMBP2; CYP2J2; MIR3117; ATF5; CPT1A; GPX3; SERPINA6; HTT; POLK; EHMT2; RPSA; AR; WT1; XDH; TOP2A; GATA3; DCK; CDK2; AKR1C3; DOK5; TOP1; THRB; PNPLA3; DNMT3A; TYMSOS; TYMS; ABCC1; BMP7; GSTP1; LINC00251; MAPT; UGT1A1; ABCB1; SLCO1B1; RUNX1; SLC13A3; MAN1B1; APEX1; HDAC4; NOS3; SETD4; HDAC9; GSTA2; IKZF1; HDAC5; ABCG2; HDAC10; HDAC3; APP; CYP1A1; NRP2; NPM1; SLC15A1; ABCA1; SLCO4C1; HDAC1; TPMT; HDAC8; IDH2; ANXA5; AKR1C4; CBR1; HDAC7; KDM4E; CBFB; SLCO6A1; USP1; ABCC9; RECQL; HDAC2; SOD2; AKR7A2; SZRD1; HDAC6; ABCB11; HDAC11; FLT3; GSTM3; COL1A2; FAS; CDA; IDH1; ATP7B; ABCC10; BLM,2024-07-24,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,527.5260000000003,1.0288999999999997,5,11,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(C)=O)CC3OC1CC(N)C(O)C(C)O1,<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia> <TARGET=MTHFR; SLC22A7; SLC22A17; TOP2B; KMT2A; MIR4268; IGHMBP2; CYP2J2; MIR3117; ATF5; CPT1A; GPX3; SERPINA6; HTT; POLK; EHMT2; RPSA; AR; WT1; XDH; TOP2A; GATA3; DCK; CDK2; AKR1C3; DOK5; TOP1; THRB; PNPLA3; DNMT3A; TYMSOS; TYMS; ABCC1; BMP7; GSTP1; LINC00251; MAPT; UGT1A1; ABCB1; SLCO1B1; RUNX1; SLC13A3; MAN1B1; APEX1; HDAC4; NOS3; SETD4; HDAC9; GSTA2; IKZF1; HDAC5; ABCG2; HDAC10; HDAC3; APP; CYP1A1; NRP2; NPM1; SLC15A1; ABCA1; SLCO4C1; HDAC1; TPMT; HDAC8; IDH2; ANXA5; AKR1C4; CBR1; HDAC7; KDM4E; CBFB; SLCO6A1; USP1; ABCC9; RECQL; HDAC2; SOD2; AKR7A2; SZRD1; HDAC6; ABCB11; HDAC11; FLT3; GSTM3; COL1A2; FAS; CDA; IDH1; ATP7B; ABCC10; BLM>
Decitabine,Y,Y,N,,N,2006.0,Y,DB01262,L01BC08,CHEMBL1201129,Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes (MDS),DNMT3A; CYP27B1; LIF; THBS1; IDH2; KRAS; CDKN2D; TP53; GSTP1; RB1; NR5A1; CDA; GMNN; TGM2; APC; MAGEA1; FLT3; CR2; HLA-E; CCND2; IDH1; CTAG1B; DNMT1; MUC2; IL2RA,2024-07-25,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,228.20799999999997,-2.1387999999999985,3,8,Nc1ncn(C2CC(O)C(CO)O2)c(=O)n1,<INDICATION=Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes (MDS)> <TARGET=DNMT3A; CYP27B1; LIF; THBS1; IDH2; KRAS; CDKN2D; TP53; GSTP1; RB1; NR5A1; CDA; GMNN; TGM2; APC; MAGEA1; FLT3; CR2; HLA-E; CCND2; IDH1; CTAG1B; DNMT1; MUC2; IL2RA>
Degarelix,Y,Y,N,,N,2008.0,N,DB06699,L02BX02,CHEMBL415606,Advanced Prostate Cancer,GNRHR; GNRHR2,2024-07-24,CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C,1632.2890000000002,1.5146999999999755,17,18,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Dexamethasone,Y,Y,N,,Y,1958.0,Y,DB01234,S03BA01; S02BA06; S01CB01; S01BA01; R01AD03; H02AB02; D10AA03; D07XB05; D07AB19; C05AA09; A01AC02,CHEMBL384467,"Leukemia, Acute; Malignant Lymphomas; Multiple Myeloma (MM); Mycosis Fungoides (MF)",NR3C1; ANXA1; CDK4; CYP2C9; F2RL1; KDR; NRG1; NFE2L2; PTGDR; CHKA; CCL17; RARA; AR; TSC22D3; PZP; DOK5; HSPA8; CDK6; BDM; HTR7; SOAT1; CD86; CARTPT; CRISPLD2; GATA3; SI; CYP2C19; APOB; NR5A1; DPEP1; BMP7; FABP1; RPS19; CYP3A4; CDH17; CHRM3; PYGL; TDO2; CTNNB1; HYAL2; SAG; TYMS; ACTC1; MT1F; GSTP1; TJP1; THRSP; JAK3; S100A10; UBR1; NR1I2; NTRK1; AGTR1; PTH1R; F9; TEAD1; SLC2A4; VEGFA; KRT19; FOLR1; RET; SFTPA1; NPPC; CDK2; SDS; CYP1A2; TGFBR3; BIRC5; VCAM1; GGT1; LIF; IRS2; NR3C2; SERPINE1; IGFBP1; LINC00251; CYP2D6; CHAT; GLS; ALK; UGT1A1; BCL2L11; SMAD3; JUNB; TG; RELA,2024-07-25,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,392.4670000000001,1.8957,3,5,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,"<INDICATION=Leukemia, Acute; Malignant Lymphomas; Multiple Myeloma (MM); Mycosis Fungoides (MF)> <TARGET=NR3C1; ANXA1; CDK4; CYP2C9; F2RL1; KDR; NRG1; NFE2L2; PTGDR; CHKA; CCL17; RARA; AR; TSC22D3; PZP; DOK5; HSPA8; CDK6; BDM; HTR7; SOAT1; CD86; CARTPT; CRISPLD2; GATA3; SI; CYP2C19; APOB; NR5A1; DPEP1; BMP7; FABP1; RPS19; CYP3A4; CDH17; CHRM3; PYGL; TDO2; CTNNB1; HYAL2; SAG; TYMS; ACTC1; MT1F; GSTP1; TJP1; THRSP; JAK3; S100A10; UBR1; NR1I2; NTRK1; AGTR1; PTH1R; F9; TEAD1; SLC2A4; VEGFA; KRT19; FOLR1; RET; SFTPA1; NPPC; CDK2; SDS; CYP1A2; TGFBR3; BIRC5; VCAM1; GGT1; LIF; IRS2; NR3C2; SERPINE1; IGFBP1; LINC00251; CYP2D6; CHAT; GLS; ALK; UGT1A1; BCL2L11; SMAD3; JUNB; TG; RELA>"
Diethylstilbestrol,N,N,Y,,N,1973.0,N,DB00255,G03CC05; G03CB02; L02AA01,CHEMBL411,,BDNF; ESRRB; SLC5A7; GMNN; PTGES3; CYP3A4; AMH; RORC; HRAS; CYP2D6; ESR2; BDKRB2; NPPC; LPO; BDKRB1; CYP1A2; AR; CP; NR1H4; CYP2C19; CYP2C9; NFE2L2; TP53; ERBB2; E2F1; BCYRN1P2; NR1I2; ESRRG; WNT7A; MYC; DNMT1; BCL2; ESR1,2024-07-24,CCC(=C(CC)C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,268.356,4.828600000000005,2,2,CCC(=C(CC)c1ccc(O)cc1)c1ccc(O)cc1,<INDICATION=nan> <TARGET=BDNF; ESRRB; SLC5A7; GMNN; PTGES3; CYP3A4; AMH; RORC; HRAS; CYP2D6; ESR2; BDKRB2; NPPC; LPO; BDKRB1; CYP1A2; AR; CP; NR1H4; CYP2C19; CYP2C9; NFE2L2; TP53; ERBB2; E2F1; BCYRN1P2; NR1I2; ESRRG; WNT7A; MYC; DNMT1; BCL2; ESR1>
Docetaxel,Y,Y,N,,Y,1996.0,Y,DB01248,L01CD02,CHEMBL92,"Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer",TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3,2024-07-24,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,807.8900000000004,3.259600000000003,5,14,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Doxorubicin,N,Y,Y,,Y,1974.0,Y,DB00997,L01DB01,CHEMBL53463,"Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma",ALDH3A1; XIAP; LRP1B; MTHFD1; RARA; BRCA1; PNPLA3; TOP2A; POLK; YWHAG; PAX8; PIK3CB; APEX1; XRCC1; CYP3A4; RXRA; MYOD1; UGT1A1; ABCB11; ZEB1; TET2; CYP2C19; FANCD2; LINC00251; ABCC9; TP53; PIK3CA; AKR7A2; RPSA; TOP2B; MAPK14; SOD2; IL11; HSP90AB1; PIK3CG; WRN; ATM; MGMT; SETD4; CYP2C9; USP1; THRB; RALBP1; RECQL; TPMT; ESR1; SLCO1B1; BDNF; CYP1B1; PLG; EHMT2; IGHMBP2; TGFB1; SRC; MAPK1; CBR1; SDHB; NR1I2; ABCB1; CPT1A; GSTM1; NT5E; SMAD3; HSP90AA1; SLCO6A1; BCL2; COL1A2; BMP7; SERPINA6; AKR1C3; KLC3; SLC22A17; FCGR3B; TAF1; ERCC1; MYB; AR; CAST; NTRK2; ABCC10; NR1H4; CYP1A1; DOK5; GADD45A; XPC; GATA3; BLM; CASP3; ATXN2; ALK; DNMT3A; CYP3A; S100A4; AFP; SLC15A1; MSH2; POLH; GPX3; IDH1; GSR; GBX2; TOP1; NQO1; FASLG; CYP2J2; CYP2D6; BAZ2B; CLCN6; STAT6; ABCA1; PPARD; POLB; SNCA; CCND1; CD274; H2AX; BRAF; CYBA; MDM2; ABCG2; PPM1D; FCGR2A; APAF1; SLC13A3; GALNT14; SLC22A7; SP3; EDN1; MAPT; TGM2; BAX; NFE2L2; CDKN1B; BIRC5; GSTM3; XDH; FLT3; GABPA; ERCC2; CYP1A2; MTR; ABCC5; G6PD; GSTA2; ABCC3; SLCO4C1; FCGR3A; ABCC4; KRT20; KMT2A,2024-07-24,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,543.5250000000003,0.0012999999999995,6,12,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(O)C(C)O1,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma> <TARGET=ALDH3A1; XIAP; LRP1B; MTHFD1; RARA; BRCA1; PNPLA3; TOP2A; POLK; YWHAG; PAX8; PIK3CB; APEX1; XRCC1; CYP3A4; RXRA; MYOD1; UGT1A1; ABCB11; ZEB1; TET2; CYP2C19; FANCD2; LINC00251; ABCC9; TP53; PIK3CA; AKR7A2; RPSA; TOP2B; MAPK14; SOD2; IL11; HSP90AB1; PIK3CG; WRN; ATM; MGMT; SETD4; CYP2C9; USP1; THRB; RALBP1; RECQL; TPMT; ESR1; SLCO1B1; BDNF; CYP1B1; PLG; EHMT2; IGHMBP2; TGFB1; SRC; MAPK1; CBR1; SDHB; NR1I2; ABCB1; CPT1A; GSTM1; NT5E; SMAD3; HSP90AA1; SLCO6A1; BCL2; COL1A2; BMP7; SERPINA6; AKR1C3; KLC3; SLC22A17; FCGR3B; TAF1; ERCC1; MYB; AR; CAST; NTRK2; ABCC10; NR1H4; CYP1A1; DOK5; GADD45A; XPC; GATA3; BLM; CASP3; ATXN2; ALK; DNMT3A; CYP3A; S100A4; AFP; SLC15A1; MSH2; POLH; GPX3; IDH1; GSR; GBX2; TOP1; NQO1; FASLG; CYP2J2; CYP2D6; BAZ2B; CLCN6; STAT6; ABCA1; PPARD; POLB; SNCA; CCND1; CD274; H2AX; BRAF; CYBA; MDM2; ABCG2; PPM1D; FCGR2A; APAF1; SLC13A3; GALNT14; SLC22A7; SP3; EDN1; MAPT; TGM2; BAX; NFE2L2; CDKN1B; BIRC5; GSTM3; XDH; FLT3; GABPA; ERCC2; CYP1A2; MTR; ABCC5; G6PD; GSTA2; ABCC3; SLCO4C1; FCGR3A; ABCC4; KRT20; KMT2A>"
Duvelisib,Y,Y,N,,N,2018.0,N,DB11952,L01EM04,CHEMBL3039502,"Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed or Refractory Follicular Lymphoma; Refractory, relapsed small lymphocytic lymphoma",F5; TP53; PIK3CD; PIK3CG; F7; PIK3CB; F7R,2024-07-24,CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,416.87200000000007,4.483500000000003,2,6,CC(Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,"<INDICATION=Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed or Refractory Follicular Lymphoma; Refractory, relapsed small lymphocytic lymphoma> <TARGET=F5; TP53; PIK3CD; PIK3CG; F7; PIK3CB; F7R>"
Edotreotide,Y,N,N,,N,2019.0,N,DB15494,V09IX09,CHEMBL408350,Neuroendocrine Tumors,FASLG,2024-07-24,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(CO)C(C)O)O,1421.6650000000004,-3.4669000000000176,17,22,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Eflornithine,N,Y,N,,Y,2023.0,N,DB06243,L01XX79,CHEMBL830,High Risk Neuroblastoma,XIAP; JUN; EHMT2; ODC1; NR5A1; TGM2; KCNA1; MYCN; PRL; ATF2; SMOX,2024-07-24,C(CC(C(F)F)(C(=O)O)N)CN,182.17,-0.2274999999999994,3,3,NCCCC(N)(C(=O)O)C(F)F,<INDICATION=High Risk Neuroblastoma> <TARGET=XIAP; JUN; EHMT2; ODC1; NR5A1; TGM2; KCNA1; MYCN; PRL; ATF2; SMOX>
Elacestrant,Y,Y,N,,N,2023.0,N,DB06374,L02BA04,CHEMBL4297509,"Advanced Breast Cancer, Metastatic Breast Cancer",ESR1; ERBB2,2024-07-24,CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)C3CCC4=C(C3)C=CC(=C4)O,458.64600000000024,5.851800000000007,2,4,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2C2CCc3cc(O)ccc3C2)cc1,"<INDICATION=Advanced Breast Cancer, Metastatic Breast Cancer> <TARGET=ESR1; ERBB2>"
Enasidenib,N,Y,N,,N,2017.0,N,DB13874,L01XX59,CHEMBL3989908,Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML),IDH2; FLT3; GRB2; IDH1,2024-07-24,CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O,473.381,4.292600000000003,3,8,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,<INDICATION=Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH2; FLT3; GRB2; IDH1>
Encorafenib,Y,Y,N,,N,2018.0,N,DB11718,L01EC03,CHEMBL3301612,Metastatic Melanoma; Unresectable Melanoma,KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN,2024-07-24,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,540.0210000000002,3.908400000000001,3,9,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN>
Entrectinib,Y,Y,N,,N,2019.0,N,DB11986,L01EX14,CHEMBL1983268,"Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid",NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN,2024-07-24,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,560.649,5.026900000000004,3,6,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,"<INDICATION=Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid> <TARGET=NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN>"
Enzalutamide,Y,Y,N,,N,2012.0,N,DB08899,L02BB04,CHEMBL1082407,Metastatic Castration Resistant Prostate Cancer,BRAF; ATR; ATM; BEVI; CYP17A1; MLH1; PTEN; TP53; CDK12; PIK3CA; APC; BRCA2; AR,2024-07-24,CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C,464.4440000000002,3.992480000000003,1,4,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,<INDICATION=Metastatic Castration Resistant Prostate Cancer> <TARGET=BRAF; ATR; ATM; BEVI; CYP17A1; MLH1; PTEN; TP53; CDK12; PIK3CA; APC; BRCA2; AR>
Epirubicin,N,Y,Y,,N,1999.0,Y,DB00445,L01DB03,CHEMBL417,Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Colorectal Cancers; Hormone Refractory Prostate Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Papillary transitional cell carcinoma of bladder; Recurrent Superficial Bladder Cancer; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Stomach Tumor; Carcinoma in situ of urinary bladder,TUBB2A; HMMR; TYMSOS; FOXO1; PIK3R2; SERPINE1; ABCB1; GCKR; KCNQ1; TOP2A; GNL3; NOS1; SPIDR; TP53; PERP; ERBB2; ABCG2; ABCC2; EPHA6; MDM4; CBR3; INSR; IRS1; BCL2; SLCO1B1; CCNK; BIRC5; MISP; ABCC1; PPP2R5D; FOXP3; RBX1; CHD1; TP53AIP1; SLC28A3; IGF2BP2,2024-07-24,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,543.5250000000003,0.0012999999999995,6,12,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(O)C(C)O1,<INDICATION=Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Colorectal Cancers; Hormone Refractory Prostate Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Papillary transitional cell carcinoma of bladder; Recurrent Superficial Bladder Cancer; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Stomach Tumor; Carcinoma in situ of urinary bladder> <TARGET=TUBB2A; HMMR; TYMSOS; FOXO1; PIK3R2; SERPINE1; ABCB1; GCKR; KCNQ1; TOP2A; GNL3; NOS1; SPIDR; TP53; PERP; ERBB2; ABCG2; ABCC2; EPHA6; MDM4; CBR3; INSR; IRS1; BCL2; SLCO1B1; CCNK; BIRC5; MISP; ABCC1; PPP2R5D; FOXP3; RBX1; CHD1; TP53AIP1; SLC28A3; IGF2BP2>
Erdafitinib,Y,Y,N,,N,2019.0,N,DB12147,L01EN01,CHEMBL3545376,"Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma",SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4,2024-07-24,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,446.55500000000023,4.183600000000003,1,8,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,"<INDICATION=Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma> <TARGET=SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4>"
Eribulin,Y,Y,N,,N,2010.0,Y,DB08871,L01XX41,CHEMBL1683590,"Metastatic Liposarcoma; Refractory, metastatic Breast cancer; Unresectable Liposarcoma",TERT; TUBB2A; TUBA3E; TUBA1C; ERBB2; TUBB3; TUBB4A; TUBB1; TUBA3C; CYP3A4; ESR1; GCF1; TUBB4B; TUB; ESR2; TUBA1A; TUBB2B; TUBB; PGR; TUBB8; TUBA4A; TUBB6; CD274; TUBA1B; CDK2,2024-07-25,CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O,729.9080000000001,3.4380000000000046,2,12,C=C1CC2CCC34CC5OC6C(OC7CCC(CC(=O)CC8C(CC9OC(CCC1O2)CC(C)C9=C)OC(CC(O)CN)C8OC)OC7C6O3)C5O4,"<INDICATION=Metastatic Liposarcoma; Refractory, metastatic Breast cancer; Unresectable Liposarcoma> <TARGET=TERT; TUBB2A; TUBA3E; TUBA1C; ERBB2; TUBB3; TUBB4A; TUBB1; TUBA3C; CYP3A4; ESR1; GCF1; TUBB4B; TUB; ESR2; TUBA1A; TUBB2B; TUBB; PGR; TUBB8; TUBA4A; TUBB6; CD274; TUBA1B; CDK2>"
Erlotinib,Y,Y,N,,Y,2004.0,Y,DB00530,L01EB02,CHEMBL553,Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic,DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1,2024-07-25,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,393.4430000000002,3.405100000000002,1,7,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,<INDICATION=Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic> <TARGET=DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1>
Estramustine,N,Y,Y,,N,1981.0,N,DB01196,L01XX11,CHEMBL1575,Metastatic Hormone Refractory Prostate Cancer,TDP1; BCL2; BLM; AR; POLK; KAT2A; HEXB; VDR; KLK3; BAX; USP1,2024-07-24,CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl,440.4110000000002,5.182000000000006,1,3,CC12CCC3c4ccc(OC(=O)N(CCCl)CCCl)cc4CCC3C1CCC2O,<INDICATION=Metastatic Hormone Refractory Prostate Cancer> <TARGET=TDP1; BCL2; BLM; AR; POLK; KAT2A; HEXB; VDR; KLK3; BAX; USP1>
Etoposide,N,Y,Y,,Y,1983.0,Y,DB00773,L01CB01,CHEMBL44657,"Acute Lymphoblastic Leukaemias (ALL); Acute Myeloid Leukemia (AML); Advanced Hodgkin's Lymphoma; Ewing's Sarcoma; Merkel cell cancer; Multiple Myeloma (MM); Neuroblastomas; Neuroendocrine Tumours; Non-Hodgkin's Lymphoma (NHL); Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Prostate Cancer; Retinoblastoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Wilms' tumor; Locally advanced Thymoma; Metastatic Thymic Cancer; Refractory Sarcoma; Refractory Testicular cancer",GDF15; SLCO1B1; NCOA3; ITGAL; TOP2A; ALK; MAPK1; PLA2G6; MYCN; ABCC1; ABCC3; TP53; AFP; ATM; CHEK1; CYP2D6; FGFR1; SLC2A4; NTRK3; TNFSF13B; HSPB2; KLK3; TYMS; CYP3A4; GSTT1; TOP2B; TBP; GMNN; NR4A1; PGP; SF3B1; DDIT3; SLIT1; NQO1; BLMH; BCL2; IGF2; BAX; TGFB1; CYP2C19; XIAP; GBX2; PLA2G1B; PAPOLA; NCOA1; GSTM1; DYNC2H1; MUC16; BTF3P11; CYP2C9; UGT1A10; GLP1R; TYMSOS; ACTR2; MAPK3; EIF4E; YAP1; CYP1A2; E2F1,2024-07-24,CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,588.5620000000005,1.3385999999999991,3,13,COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Myeloid Leukemia (AML); Advanced Hodgkin's Lymphoma; Ewing's Sarcoma; Merkel cell cancer; Multiple Myeloma (MM); Neuroblastomas; Neuroendocrine Tumours; Non-Hodgkin's Lymphoma (NHL); Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Prostate Cancer; Retinoblastoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Wilms' tumor; Locally advanced Thymoma; Metastatic Thymic Cancer; Refractory Sarcoma; Refractory Testicular cancer> <TARGET=GDF15; SLCO1B1; NCOA3; ITGAL; TOP2A; ALK; MAPK1; PLA2G6; MYCN; ABCC1; ABCC3; TP53; AFP; ATM; CHEK1; CYP2D6; FGFR1; SLC2A4; NTRK3; TNFSF13B; HSPB2; KLK3; TYMS; CYP3A4; GSTT1; TOP2B; TBP; GMNN; NR4A1; PGP; SF3B1; DDIT3; SLIT1; NQO1; BLMH; BCL2; IGF2; BAX; TGFB1; CYP2C19; XIAP; GBX2; PLA2G1B; PAPOLA; NCOA1; GSTM1; DYNC2H1; MUC16; BTF3P11; CYP2C9; UGT1A10; GLP1R; TYMSOS; ACTR2; MAPK3; EIF4E; YAP1; CYP1A2; E2F1>"
Everolimus,Y,Y,N,,N,2009.0,Y,DB01590,L04AA18; L01EG02,CHEMBL1908360,"Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors",PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET,2024-07-25,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,958.24,6.197200000000008,3,14,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,"<INDICATION=Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors> <TARGET=PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET>"
Exemestane,N,Y,Y,,N,1999.0,Y,DB00990,L02BG06,CHEMBL1200374,"Early Breast Cancer; Refractory, advanced Breast cancer",CYP19A1; TCL1A; BGLAP; STK11; ESR1; ESR2; MAP4K4; CYP1B1; PGR; CPD; IGF1R; AKR1C3; NFE2L2; TUBB1; CCDC148; AR; ERBB2,2024-07-24,CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C,296.40999999999997,4.029500000000003,0,2,C=C1CC2C(CCC3(C)C(=O)CCC23)C2(C)C=CC(=O)C=C12,"<INDICATION=Early Breast Cancer; Refractory, advanced Breast cancer> <TARGET=CYP19A1; TCL1A; BGLAP; STK11; ESR1; ESR2; MAP4K4; CYP1B1; PGR; CPD; IGF1R; AKR1C3; NFE2L2; TUBB1; CCDC148; AR; ERBB2>"
Fedratinib,Y,Y,N,,N,2019.0,N,DB12500,L01EJ02,CHEMBL1287853,,JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1,2024-07-24,CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4,524.6910000000004,4.823620000000004,3,8,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,<INDICATION=nan> <TARGET=JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1>
Fludarabine,N,Y,Y,,Y,1991.0,Y,DB01073,L01BB05,CHEMBL1568,B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory; Refractory Non-Hodgkin's lymphoma,MPO; NFE2L2; IKZF1; RRM1; POLA1; POLE3; PRIM2; BAX; POLD2; ADH1A; ATM; RRM2B; PIK3CG; POLA2; SLCO1B1; CYP2E1; POLD3; SLC29A1; SMAD3; POLD4; CXCL12; POLD1; POLE; SULT2B1; POLE2; DCK; SLC22A12; XIAP; RRM2; NIPSNAP2; PRIM1; GBA1LP; ADA; CD40,2024-07-24,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N,285.23500000000007,-1.8409,4,9,Nc1nc(F)nc2c1ncn2C1OC(CO)C(O)C1O,<INDICATION=B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory; Refractory Non-Hodgkin's lymphoma> <TARGET=MPO; NFE2L2; IKZF1; RRM1; POLA1; POLE3; PRIM2; BAX; POLD2; ADH1A; ATM; RRM2B; PIK3CG; POLA2; SLCO1B1; CYP2E1; POLD3; SLC29A1; SMAD3; POLD4; CXCL12; POLD1; POLE; SULT2B1; POLE2; DCK; SLC22A12; XIAP; RRM2; NIPSNAP2; PRIM1; GBA1LP; ADA; CD40>
Fluorouracil,N,Y,Y,,Y,1962.0,Y,DB00544,L01BC02,CHEMBL185,Breast Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Rectal Carcinoma; Superficial Basal Cell Carcinoma,OR10AE3P; PERP; BDNF; GCKR; MECP2; RGS5; GNL3; NOS1; TYMS; FPGS; MUC2; DPYD; FOXO1; FGFR4; ABCC4; REV3L; HSPA5; IL11; CYP19A1; KRAS; CSPG4; PIK3R2; CYP3A4; CD274; ERCC1; LGR5; DLG5; OSGEP; TOP2A; NRAS; FAS; TP53AIP1; IGFBP3; MEGF11; XRCC3; CYP3A; KLC1; WNT5B; ATRX; PPP2R5D; ALCAM; EGFR; BRAF; PTEN; KCNQ1; IL6R; TMEM167A; SLC19A1; EXO1; ATM; CYP2E1; PIK3CA; ABCC1; TSHB; HBB; ITGAL; AURKA; DTYMK; CBR1; MSH6; E2F1; PMS2; ABCC2; ABCB1; CHN2; BIRC5; NT5C1A; RALBP1; CYP4X1; TP53; KLC3; ENOSF1; SELE; SCN1A; SMAD4; TYMP; TYMSOS; IGF2BP2; UPB1; RBX1; TWIST1; ABCC5; FGFR2; PTPRC; TPT1; COLEC10; CBR3; CXCL8; CYP2C8; PARD3B; CDKN1A; CYP2C19; PSMB3P1; MSH2; SLC22A16; DKK1; MLH1; MYB; CYP1B1; PDGFRB; MUTYH; IL2RA; CCNK; INSR; ALDH3A1; IRS1; GALNT14; APEX1; BAX; MAP2K1; GNAS; KEAP1; CYP2A6; HMMR; CCND1; CDC25C; NLGN1; MTHFR; ABCG1,2024-07-25,C1=C(C(=O)NC(=O)N1)F,130.07799999999995,-0.7977000000000001,2,2,O=c1[nH]cc(F)c(=O)[nH]1,<INDICATION=Breast Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Rectal Carcinoma; Superficial Basal Cell Carcinoma> <TARGET=OR10AE3P; PERP; BDNF; GCKR; MECP2; RGS5; GNL3; NOS1; TYMS; FPGS; MUC2; DPYD; FOXO1; FGFR4; ABCC4; REV3L; HSPA5; IL11; CYP19A1; KRAS; CSPG4; PIK3R2; CYP3A4; CD274; ERCC1; LGR5; DLG5; OSGEP; TOP2A; NRAS; FAS; TP53AIP1; IGFBP3; MEGF11; XRCC3; CYP3A; KLC1; WNT5B; ATRX; PPP2R5D; ALCAM; EGFR; BRAF; PTEN; KCNQ1; IL6R; TMEM167A; SLC19A1; EXO1; ATM; CYP2E1; PIK3CA; ABCC1; TSHB; HBB; ITGAL; AURKA; DTYMK; CBR1; MSH6; E2F1; PMS2; ABCC2; ABCB1; CHN2; BIRC5; NT5C1A; RALBP1; CYP4X1; TP53; KLC3; ENOSF1; SELE; SCN1A; SMAD4; TYMP; TYMSOS; IGF2BP2; UPB1; RBX1; TWIST1; ABCC5; FGFR2; PTPRC; TPT1; COLEC10; CBR3; CXCL8; CYP2C8; PARD3B; CDKN1A; CYP2C19; PSMB3P1; MSH2; SLC22A16; DKK1; MLH1; MYB; CYP1B1; PDGFRB; MUTYH; IL2RA; CCNK; INSR; ALDH3A1; IRS1; GALNT14; APEX1; BAX; MAP2K1; GNAS; KEAP1; CYP2A6; HMMR; CCND1; CDC25C; NLGN1; MTHFR; ABCG1>
Fluoxymesterone,N,Y,N,,N,1956.0,Y,DB01185,G03BA01,CHEMBL1445,"Inoperable, metastatic Breast cancer",AR; NR3C1; BEVI; PRL,2024-07-24,CC12CCC(=O)C=C1CCC3C2(C(CC4(C3CCC4(C)O)C)O)F,336.447,3.3322000000000025,2,3,CC1(O)CCC2C3CCC4=CC(=O)CCC4(C)C3(F)C(O)CC21C,"<INDICATION=Inoperable, metastatic Breast cancer> <TARGET=AR; NR3C1; BEVI; PRL>"
Flutamide,N,Y,Y,,N,1989.0,Y,DB00499,L02BB01,CHEMBL806,C Prostatic Carcinoma; Stage B2 Prostatic Carcinoma; Stage D2 Prostatic carcinoma,CYP1A2; RORC; KLK3; AR; EHMT2; NFE2L2; CYP3A4; G6PD; TH; VIP; CYP2C19; CYP2C9; NR1I2; BIRC5; PEBP1; MPO; IL2RA; BEVI; AQP9; CDKN1A,2024-07-24,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,276.21399999999994,3.2081000000000017,1,3,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,<INDICATION=C Prostatic Carcinoma; Stage B2 Prostatic Carcinoma; Stage D2 Prostatic carcinoma> <TARGET=CYP1A2; RORC; KLK3; AR; EHMT2; NFE2L2; CYP3A4; G6PD; TH; VIP; CYP2C19; CYP2C9; NR1I2; BIRC5; PEBP1; MPO; IL2RA; BEVI; AQP9; CDKN1A>
Fotemustine,Y,N,N,,N,,,DB04106,L01AD05,CHEMBL549386,Metastatic Melanoma,MGMT; TXNRD1,2024-02-07,CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC,315.6940000000001,2.5303000000000004,1,6,CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O,<INDICATION=Metastatic Melanoma> <TARGET=MGMT; TXNRD1>
Fruquintinib,Y,Y,N,,N,2023.0,N,DB11679,L01EK04,CHEMBL4303214,Metastatic Colorectal Cancer,KDR; DRD1; FLT1; DRD2; FLT4; DRD3; KRAS,2024-07-24,CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC,393.39900000000017,3.853520000000003,1,7,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,<INDICATION=Metastatic Colorectal Cancer> <TARGET=KDR; DRD1; FLT1; DRD2; FLT4; DRD3; KRAS>
Fulvestrant,Y,Y,N,,N,2002.0,Y,DB00947,L02BA03,CHEMBL1358,"Advanced or Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer",TP53; PGR; ESR2; ESR1; EML4; NOS1; EPHX2; ESRRA; FGF2; ERBB2; PIK3CA; PIK3CG; TFPI; BCYRN1P2; PTEN; RB1; CYP1A2; FGFR2; CCNE1; CDK6; XIAP; ALK; ALDH3B1; BDNF,2024-07-25,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,606.7820000000008,8.682600000000004,2,3,CC12CCC3c4ccc(O)cc4CC(CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)C3C1CCC2O,"<INDICATION=Advanced or Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=TP53; PGR; ESR2; ESR1; EML4; NOS1; EPHX2; ESRRA; FGF2; ERBB2; PIK3CA; PIK3CG; TFPI; BCYRN1P2; PTEN; RB1; CYP1A2; FGFR2; CCNE1; CDK6; XIAP; ALK; ALDH3B1; BDNF>"
Futibatinib,Y,Y,N,,N,2022.0,N,DB15149,L01EN04,CHEMBL3701238,"Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma",NRAS; FGFR3; FGFR4; SLC26A3; DPYSL2; BRAF; DR1; PIK3CA; FGFR1; FGFR2; DPYSL3,2024-07-24,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,418.4570000000003,1.7849000000000004,1,8,C=CC(=O)N1CCC(n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,"<INDICATION=Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma> <TARGET=NRAS; FGFR3; FGFR4; SLC26A3; DPYSL2; BRAF; DR1; PIK3CA; FGFR1; FGFR2; DPYSL3>"
Gefitinib,Y,Y,N,,Y,2003.0,Y,DB00317,L01EB01,CHEMBL939,Metastatic Non-Small Cell Lung Cancer,PRKD3; EGFR; DXO; HIPK4; MAPK9; TNK2; PLAU; CYP2C9; CHEK2; PHKG2; MET; NUP62; BRAF; FGFR3; BLK; PBK; ERBB3; FRK; IGF1R; MINK1; MAP4K5; ROS1; ERBB4; MAP4K4; LYN; MAPK8; KEAP1; CYP2D6; MAPK14; CRKL; ABCB1; MAPK10; EMP1; SIK2; PRKD2; IRAK4; ALK; CAMK2G; YES1; UHRF1; MAPT; IGF2; PTEN; CAMK2D; SMO; PIM3; ARF1; MAP3K1; SIRT2; HCK; MKNK2; DVL2; LIMK1; PIK3CA; BRSK1; CYP3A5; FLT4; KRAS; ERBB2; LCK; GMNN; CSNK1D; RELA; PIM1; AXL; CEACAM5; SLK; IRAK1,2024-07-24,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,446.9100000000004,4.2756000000000025,1,7,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=PRKD3; EGFR; DXO; HIPK4; MAPK9; TNK2; PLAU; CYP2C9; CHEK2; PHKG2; MET; NUP62; BRAF; FGFR3; BLK; PBK; ERBB3; FRK; IGF1R; MINK1; MAP4K5; ROS1; ERBB4; MAP4K4; LYN; MAPK8; KEAP1; CYP2D6; MAPK14; CRKL; ABCB1; MAPK10; EMP1; SIK2; PRKD2; IRAK4; ALK; CAMK2G; YES1; UHRF1; MAPT; IGF2; PTEN; CAMK2D; SMO; PIM3; ARF1; MAP3K1; SIRT2; HCK; MKNK2; DVL2; LIMK1; PIK3CA; BRSK1; CYP3A5; FLT4; KRAS; ERBB2; LCK; GMNN; CSNK1D; RELA; PIM1; AXL; CEACAM5; SLK; IRAK1>
Gemcitabine,N,Y,Y,,Y,1996.0,Y,DB00441,L01BC05,CHEMBL888,"Advanced Ovarian Cancer; Bladder Transitional Cell Carcinoma Stage IV; Cervical Cancers; Cutaneous T-Cell Lymphoma (CTCL); Head and Neck Carcinoma; Hodgkins Disease (HD); Locally Advanced Pancreatic Adenocarcinoma; Mesothelioma; Metastatic Breast Cancer; Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer (NSCLC), Stage IV; Non-small Cell Lung Cancer Stage IIIA; Small Cell Lung Cancer (SCLC); Stage 4 Pancreatic adenocarcinoma",C6orf15; CYP2C8; NIPSNAP2; ATAT1; AR; WWOX; BRCA2; MDM2; GPX5; SLC29A1; RRM1; POLD1; RAF1; CIP2A; POLE3; TP53; POLD2; POLD4; FKBP5; CHEK1; FANCC; POLD3; CD274; FGFR3; XRCC1; PRIM2; NRAS; POLE2; SERPINC1; POLE; PSORS1C1; TNF; DDX53; NT5C; SERPINA5; RRM2B; BRCA1; PPP1R18; PRB2; CDA; DCP1B; CAMK4; UBASH3B; PRRC2A; MTHFD1; SH2D5; BRAF; PPP1R13L; TNC; OR4D6; DOCK8; PTEN; SLCO1B1; FHL2; IGF2; PPCDC; GBA1LP; ERCC1; RRM2; HCP5; MS4A2; HRAS; ESR2; PIK3CA; SMAD4; POLR1G; MTHFR; ETS2; CDKN2A; CDSN; NT5C1A; SLC29A2; BAZ2B; ACSS2; ALG10; NRG1; MUCL3; HLA-C; WEE1; CDC5L; BTRC; KLC3; XYLT2; MSH5; PRIM1; ALOX5AP; TGM2; CBL; KRAS; TENT4A; ERBB2; POLA2; POLA1,2024-07-24,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,263.2,-1.2886000000000004,3,7,Nc1ccn(C2OC(CO)C(O)C2(F)F)c(=O)n1,"<INDICATION=Advanced Ovarian Cancer; Bladder Transitional Cell Carcinoma Stage IV; Cervical Cancers; Cutaneous T-Cell Lymphoma (CTCL); Head and Neck Carcinoma; Hodgkins Disease (HD); Locally Advanced Pancreatic Adenocarcinoma; Mesothelioma; Metastatic Breast Cancer; Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer (NSCLC), Stage IV; Non-small Cell Lung Cancer Stage IIIA; Small Cell Lung Cancer (SCLC); Stage 4 Pancreatic adenocarcinoma> <TARGET=C6orf15; CYP2C8; NIPSNAP2; ATAT1; AR; WWOX; BRCA2; MDM2; GPX5; SLC29A1; RRM1; POLD1; RAF1; CIP2A; POLE3; TP53; POLD2; POLD4; FKBP5; CHEK1; FANCC; POLD3; CD274; FGFR3; XRCC1; PRIM2; NRAS; POLE2; SERPINC1; POLE; PSORS1C1; TNF; DDX53; NT5C; SERPINA5; RRM2B; BRCA1; PPP1R18; PRB2; CDA; DCP1B; CAMK4; UBASH3B; PRRC2A; MTHFD1; SH2D5; BRAF; PPP1R13L; TNC; OR4D6; DOCK8; PTEN; SLCO1B1; FHL2; IGF2; PPCDC; GBA1LP; ERCC1; RRM2; HCP5; MS4A2; HRAS; ESR2; PIK3CA; SMAD4; POLR1G; MTHFR; ETS2; CDKN2A; CDSN; NT5C1A; SLC29A2; BAZ2B; ACSS2; ALG10; NRG1; MUCL3; HLA-C; WEE1; CDC5L; BTRC; KLC3; XYLT2; MSH5; PRIM1; ALOX5AP; TGM2; CBL; KRAS; TENT4A; ERBB2; POLA2; POLA1>"
Gilteritinib,Y,Y,N,,N,2018.0,N,DB12141,L01EX13,CHEMBL3301622,Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations,HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B,2024-07-24,CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5,552.7240000000004,2.697200000000002,3,10,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,<INDICATION=Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations> <TARGET=HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B>
Glasdegib,Y,Y,N,,N,2018.0,N,DB11978,L01XJ03,CHEMBL2043437,Acute Myeloid Leukemia (AML),SMO; ALOX12; MTOR; FLT3,2024-07-24,CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N,374.44800000000015,3.391580000000001,3,4,CN1CCC(NC(=O)Nc2ccc(C#N)cc2)CC1c1nc2ccccc2[nH]1,<INDICATION=Acute Myeloid Leukemia (AML)> <TARGET=SMO; ALOX12; MTOR; FLT3>
Goserelin,N,Y,Y,,N,1989.0,N,DB00014,L02AE03,CHEMBL1201247,Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate,ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR,2024-07-24,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,1269.4330000000004,-3.105700000000025,17,16,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Histamine dihydrochloride,Y,Y,N,,N,1939.0,N,DB05381,L03AX14,CHEMBL90,Acute Myeloid Leukaemia,AMD1; HRH2; UBE2K; HRH3; GLUD1P3; HRH1; EHMT2; AMELX; SLC29A4; HRH4; GAPDH; USP1; LMNA,2024-07-24,C1=C(NC=N1)CCN.Cl.Cl,184.07,0.7544999999999997,2,2,Cl.Cl.NCCc1cnc[nH]1,<INDICATION=Acute Myeloid Leukaemia> <TARGET=AMD1; HRH2; UBE2K; HRH3; GLUD1P3; HRH1; EHMT2; AMELX; SLC29A4; HRH4; GAPDH; USP1; LMNA>
Histrelin,N,Y,N,,N,1991.0,N,DB06788,L02AE05,CHEMBL1201255,Advanced Prostate Cancer,GNRHR; GNRHR2,2024-02-07,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC2=CN(C=N2)CC3=CC=CC=C3)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8,1323.5280000000005,-0.9967000000000052,15,16,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Hydroxyurea,N,Y,N,,N,1967.0,Y,DB01005,L01XX05,CHEMBL467,"Essential Thrombocythemia (ET); Head and Neck Carcinoma; Melanomas; Ovarian Cancer Metastatic; Polycythemia Vera (PV); Chronic, refractory Myeloid Leukemia; Inoperable Ovarian cancer",BLM; PTH; DNMT1; EIF4E; JAK2; TET2; ABL1; MAP3K5; DUSP1; GBA1LP; RRM1; CP; HRAS; ASS1; SIN3A; CYP3A4; NIPSNAP2; KLF4; RRM2B; RRM2; DNTT,2024-07-25,C(=O)(N)NO,76.05499999999999,-0.9561000000000002,3,2,NC(=O)NO,"<INDICATION=Essential Thrombocythemia (ET); Head and Neck Carcinoma; Melanomas; Ovarian Cancer Metastatic; Polycythemia Vera (PV); Chronic, refractory Myeloid Leukemia; Inoperable Ovarian cancer> <TARGET=BLM; PTH; DNMT1; EIF4E; JAK2; TET2; ABL1; MAP3K5; DUSP1; GBA1LP; RRM1; CP; HRAS; ASS1; SIN3A; CYP3A4; NIPSNAP2; KLF4; RRM2B; RRM2; DNTT>"
Ibrutinib,Y,Y,N,,N,2013.0,N,DB09053,L01EL01,CHEMBL1873475,Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom's Macroglobulinemia (WM),CSF3R; BTK; ATM; EGFR; PLCG2; EPHX2; EPHB3; FLT3; MS4A2; MYD88; EFNA1; EEGV1; LYN; ERBB2; EPS15; PIM1; FGR; YES1; MYC; EFNB2; EN1; TEC; FKBP1AP3; TP53; CYP2D6; ERBB4; DXO; ENO2; BMX; EPHA8; SMAD3; BLK; ENUR2,2024-07-24,C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N,440.5070000000002,4.2173000000000025,1,7,C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom's Macroglobulinemia (WM)> <TARGET=CSF3R; BTK; ATM; EGFR; PLCG2; EPHX2; EPHB3; FLT3; MS4A2; MYD88; EFNA1; EEGV1; LYN; ERBB2; EPS15; PIM1; FGR; YES1; MYC; EFNB2; EN1; TEC; FKBP1AP3; TP53; CYP2D6; ERBB4; DXO; ENO2; BMX; EPHA8; SMAD3; BLK; ENUR2>
Idarubicin,N,Y,Y,,N,1990.0,Y,DB01177,L01DB06,CHEMBL1117,Acute Myeloid Leukemia (AML),CBX1; CBR3; CYP2E1; CSF2; POLH; RAPGEF3; FLT3; POLB; SLCO1B1; ETV6; POLI; NQO1; TOP2A; SULT2B1; THRB; ATAD5; FEN1; KCNH2; MPHOSPH8; APEX1; EHMT2; ABCB1; ATXN2; WRN; DRD1; IDH1; MTOR; ERG; PPARD; NT5C3A; HTT; AR; NCF4; USP1; BLM; RECQL; quinone dehydrogenase 2; SLC22A12; DCK; MAPT; BRD10; ADH1A; POLK; RAC2; PLK1; DNMT3A; CYBA; RAPGEF4,2024-07-24,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,497.5000000000002,1.0203,5,10,CC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(N)C(O)C(C)O2)C1)C(=O)c1ccccc1C3=O,<INDICATION=Acute Myeloid Leukemia (AML)> <TARGET=CBX1; CBR3; CYP2E1; CSF2; POLH; RAPGEF3; FLT3; POLB; SLCO1B1; ETV6; POLI; NQO1; TOP2A; SULT2B1; THRB; ATAD5; FEN1; KCNH2; MPHOSPH8; APEX1; EHMT2; ABCB1; ATXN2; WRN; DRD1; IDH1; MTOR; ERG; PPARD; NT5C3A; HTT; AR; NCF4; USP1; BLM; RECQL; quinone dehydrogenase 2; SLC22A12; DCK; MAPT; BRD10; ADH1A; POLK; RAC2; PLK1; DNMT3A; CYBA; RAPGEF4>
Idelalisib,Y,Y,N,,N,2014.0,N,DB09054,L01EM01,CHEMBL2216870,Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma,PIK3CA; PIK3CD; F5; PIK3CB; BRAF; TP53; PTEN; F7; F7R,2024-07-24,CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,415.4320000000001,3.7543000000000006,2,7,CCC(Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,<INDICATION=Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma> <TARGET=PIK3CA; PIK3CD; F5; PIK3CB; BRAF; TP53; PTEN; F7; F7R>
Ifosfamide,N,Y,Y,,Y,1988.0,Y,DB01181,L01AA06,CHEMBL1024,"Cancer, Bladder; Cervical Cancers; Ewing's Sarcoma; Head and Neck Carcinoma; Lymphoma, Hodgkins; Malignant Neoplasm of Pancreas; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Testicular Germ Cell Cancer; Advanced thymic carcinoma",TERC; KLC3; IL6; CYP2A6; DNMT1; GSTP1; TP53; ALDH1A1; CYP2B6; ERCC2; ALK; HSPA4; NR1I2; MGMT,2024-07-24,C1CN(P(=O)(OC1)NCCCl)CCCl,261.08899999999994,1.884,1,2,O=P1(NCCCl)OCCCN1CCCl,"<INDICATION=Cancer, Bladder; Cervical Cancers; Ewing's Sarcoma; Head and Neck Carcinoma; Lymphoma, Hodgkins; Malignant Neoplasm of Pancreas; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Testicular Germ Cell Cancer; Advanced thymic carcinoma> <TARGET=TERC; KLC3; IL6; CYP2A6; DNMT1; GSTP1; TP53; ALDH1A1; CYP2B6; ERCC2; ALK; HSPA4; NR1I2; MGMT>"
Imatinib,Y,Y,N,,Y,2001.0,Y,DB00619,L01EA01,CHEMBL941,"Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor",KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT,2024-07-25,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,493.61500000000024,4.590320000000003,2,7,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,"<INDICATION=Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor> <TARGET=KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT>"
Imiquimod,Y,Y,N,,N,1997.0,Y,DB00724,D06BB10,CHEMBL1282,Superficial Basal Cell Carcinoma,TLR7; IFNA1; SARDH; GMNN,2024-07-25,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,240.31,2.8227,1,4,CC(C)Cn1cnc2c(N)nc3ccccc3c21,<INDICATION=Superficial Basal Cell Carcinoma> <TARGET=TLR7; IFNA1; SARDH; GMNN>
Inavolisib,N,Y,N,,N,2024.0,,DB15275,,CHEMBL4650215,Locally advanced or metastatic breast cancer,PIK3CG; FGFR2; PIK3CA,2024-11-28,CC(C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4C(COC4=O)C(F)F,407.3770000000001,1.8184999999999996,2,7,CC(Nc1ccc2c(c1)OCCn1cc(N3C(=O)OCC3C(F)F)nc1-2)C(N)=O,<INDICATION=Locally advanced or metastatic breast cancer> <TARGET=PIK3CG; FGFR2; PIK3CA>
Infigratinib,N,Y,N,,N,2021.0,N,DB11886,L01EN03,CHEMBL1852688,"Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas",FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3,2024-07-24,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,560.4860000000003,5.3544000000000045,2,8,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3>"
Interferon Alfa-2b,Y,Y,N,,N,1986.0,N,DB00105,L03AB05,CHEMBL1201558,"Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant",IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX,2024-07-24,CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2.C(S(=O)(=O)[O-])(I)I.[Na+],746.5520000000001,2.2916000000000007,0,7,CCCN(CCOc1c(Cl)cc(Cl)cc1Cl)C(=O)n1ccnc1.O=S(=O)([O-])C(I)I.[Na+],"<INDICATION=Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant> <TARGET=IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX>"
Iobenguane I-131,N,Y,N,,N,1994.0,N,DB06704,V09IX01; V09IX02; V10XA02,CHEMBL1615779,"Metastatic Pheochromocytoma; Metastatic Neuroblastoma; Primary Neuroblastomas; Primary Pheochromocytomas; Unresectable, locally advanced iobenguane-scan positive Paraganglioma; Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas; Unresectable, metastatic iobenguane-scan positive Paraganglioma; Unresectable, metastatic iobenguane-scan positive Pheochromocytomas",SLC6A2; TH,2024-07-24,C1=CC(=CC(=C1)I)CN=C(N)N,275.093,1.0646000000000002,2,1,NC(N)=NCc1cccc(I)c1,"<INDICATION=Metastatic Pheochromocytoma; Metastatic Neuroblastoma; Primary Neuroblastomas; Primary Pheochromocytomas; Unresectable, locally advanced iobenguane-scan positive Paraganglioma; Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas; Unresectable, metastatic iobenguane-scan positive Paraganglioma; Unresectable, metastatic iobenguane-scan positive Pheochromocytomas> <TARGET=SLC6A2; TH>"
Irinotecan,N,Y,Y,,Y,1996.0,Y,DB00762,L01CE02,CHEMBL481,"Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma",RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274,2024-07-24,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,586.689,4.0911000000000035,1,9,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma> <TARGET=RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274>"
Ivosidenib,Y,Y,N,,N,2018.0,N,DB14568,L01XX62,CHEMBL3989958,"Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation",IDH2; GPX1P2; IDH1,2024-07-24,C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N,582.9700000000001,4.324580000000003,1,6,N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,"<INDICATION=Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation> <TARGET=IDH2; GPX1P2; IDH1>"
Ixabepilone,N,Y,N,,N,2007.0,N,DB04845,L01DC04,CHEMBL1201752,Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer,ESR1; TUBB; ERBB2; TUBA1C; TUBB2B; TUBA3C; TUBB1; TUBA4A; PGR; TUBB8; TUBA1B; TUBB3; TUBA1A; TUBB2A; ESR2; CYP3A4; TUBA3E; TUBB4B; TUBB4A; TUBB6; TUB; GCF1,2024-07-24,CC1CCCC2(C(O2)CC(NC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C,506.70900000000023,4.050520000000002,3,7,CC(=Cc1csc(C)n1)C1CC2OC2(C)CCCC(C)C(O)C(C)C(=O)C(C)(C)C(O)CC(=O)N1,<INDICATION=Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer> <TARGET=ESR1; TUBB; ERBB2; TUBA1C; TUBB2B; TUBA3C; TUBB1; TUBA4A; PGR; TUBB8; TUBA1B; TUBB3; TUBA1A; TUBB2A; ESR2; CYP3A4; TUBA3E; TUBB4B; TUBB4A; TUBB6; TUB; GCF1>
Ixazomib,Y,Y,N,,N,2015.0,N,DB09570,L01XG03,CHEMBL2141296,Multiple Myeloma (MM),PSMD6; PSMC3; PSMD13; PSMB4; PSMA4; PSMB7; PSMC6; PSMA3; PSMD3; PSMB2; PSMA1; FRA6F; PSMD2; SEM1; ADRM1; PSMB3; PSMD4; PSMA2; PSMA5; PSMD8; TP53; PSMB10; PSMB5; PSMA7; PSMD14; PSMC1; PSMC5; PSMD12; PSMA8; PSMD1; ALK; EML4; PSMB6; PSMB8; PSMC2; PSMD11; PSMB1; PSMC4; PSMA6; PSMD7; PSMB11; PSMB9,2024-07-24,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,361.034,1.2660999999999996,4,4,CC(C)CC(NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,<INDICATION=Multiple Myeloma (MM)> <TARGET=PSMD6; PSMC3; PSMD13; PSMB4; PSMA4; PSMB7; PSMC6; PSMA3; PSMD3; PSMB2; PSMA1; FRA6F; PSMD2; SEM1; ADRM1; PSMB3; PSMD4; PSMA2; PSMA5; PSMD8; TP53; PSMB10; PSMB5; PSMA7; PSMD14; PSMC1; PSMC5; PSMD12; PSMA8; PSMD1; ALK; EML4; PSMB6; PSMB8; PSMC2; PSMD11; PSMB1; PSMC4; PSMA6; PSMD7; PSMB11; PSMB9>
Lanreotide,N,Y,Y,,N,2007.0,Y,DB06791,H01CB03,CHEMBL1201185,"Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors",SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG,2024-07-25,CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N,1096.347,0.8216000000000119,13,14,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lapatinib,Y,Y,N,,N,2007.0,Y,DB01259,L01EH01,CHEMBL554,"Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer",RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1,2024-07-24,CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,581.0690000000003,6.139100000000004,2,8,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,"<INDICATION=Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1>"
Larotrectinib,Y,Y,N,,N,2018.0,N,DB14723,L01EX12,CHEMBL3889654,NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive,NTRK1; NTRK3; NTRK2; DRD5P1,2024-07-24,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,428.4430000000002,2.9475000000000016,2,6,O=C(Nc1cnn2ccc(N3CCCC3c3cc(F)ccc3F)nc12)N1CCC(O)C1,<INDICATION=NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive> <TARGET=NTRK1; NTRK3; NTRK2; DRD5P1>
Lazertinib,N,Y,N,,N,2024.0,,DB16216,L01EB09,CHEMBL4558324,First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC),EPHB3; DXO; EGFR; DRD2; FDX1,2024-11-28,CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC,554.6550000000003,4.104200000000002,2,10,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,<INDICATION=First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)> <TARGET=EPHB3; DXO; EGFR; DRD2; FDX1>
Lenalidomide,Y,Y,N,,Y,2005.0,Y,DB00480,L04AX04,CHEMBL848,Chronic Lymphocytic Leukemia (CLL) - Refractory; Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); Multiple Myeloma (MM); Myelodysplastic Syndrome; Refractory Diffuse Large B Cell Lymphoma,TNFSF11; RBX1; VEGFC; VEGFB; CUL4A; DDB1; KDR; TP53; TNF; CTNNB1; VEGFA; CRBN; FGF2,2024-07-25,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,259.265,0.0297999999999994,2,4,Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,<INDICATION=Chronic Lymphocytic Leukemia (CLL) - Refractory; Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); Multiple Myeloma (MM); Myelodysplastic Syndrome; Refractory Diffuse Large B Cell Lymphoma> <TARGET=TNFSF11; RBX1; VEGFC; VEGFB; CUL4A; DDB1; KDR; TP53; TNF; CTNNB1; VEGFA; CRBN; FGF2>
Lenvatinib,Y,Y,N,,N,2015.0,N,DB09078,L01EX08,CHEMBL1289601,Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer,DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3,2024-07-24,COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl,426.8600000000001,4.071900000000001,3,5,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,<INDICATION=Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer> <TARGET=DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3>
Letrozole,N,Y,Y,,N,1997.0,Y,DB01006,L02BG04,CHEMBL1444,Advanced Breast Cancer; Early Breast Cancer; Ovarian Epithelial Cancer; Advanced HR + HER2 - breast cancer; Metastatic HR + HER2 - breast cancer,CDKN2A; CTNNB1; PGR; ESR1; CYP2A6; SFTPA1; PIK3CA; CPD; RB1; CCDC148; CYP1B1; PTEN; MMP2; CYP3A4; KIT; CYP19A1; ERBB2; ZNF613,2024-07-25,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,285.31,2.659160000000001,0,5,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Ovarian Epithelial Cancer; Advanced HR + HER2 - breast cancer; Metastatic HR + HER2 - breast cancer> <TARGET=CDKN2A; CTNNB1; PGR; ESR1; CYP2A6; SFTPA1; PIK3CA; CPD; RB1; CCDC148; CYP1B1; PTEN; MMP2; CYP3A4; KIT; CYP19A1; ERBB2; ZNF613>
Leuprolide,N,Y,N,,N,1985.0,Y,DB00007,L02AE51; L02AE02,CHEMBL1201199,Advanced Prostate Cancer,CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4,2024-07-24,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,1209.4210000000005,-1.438100000000009,15,14,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Lomustine,N,Y,Y,,N,1976.0,N,DB01206,L01AD02,CHEMBL514,Primary Brain Tumors; Refractory Hodgkin Lymphoma; Tumors Metastatic to Brain,IDH1; MGMT; ADK; EGFR,2024-07-24,C1CCC(CC1)NC(=O)N(CCCl)N=O,233.699,2.250900000000001,1,3,O=NN(CCCl)C(=O)NC1CCCCC1,<INDICATION=Primary Brain Tumors; Refractory Hodgkin Lymphoma; Tumors Metastatic to Brain> <TARGET=IDH1; MGMT; ADK; EGFR>
Lorlatinib,Y,Y,N,,N,2018.0,N,DB12130,L01ED05,CHEMBL3286830,"Progressive, metastatic Anaplastic lymphoma kinase-positive Metastatic Non-Small Cell Lung Cancer",EML4; ROS1; FGFR1; ENO1; ALK; PIK3CA; NRAS; HRAS; RB1; TP53; BRAF; DTX1; HBEGF,2024-07-24,CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C,406.4210000000001,2.8006800000000016,1,7,CC1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,"<INDICATION=Progressive, metastatic Anaplastic lymphoma kinase-positive Metastatic Non-Small Cell Lung Cancer> <TARGET=EML4; ROS1; FGFR1; ENO1; ALK; PIK3CA; NRAS; HRAS; RB1; TP53; BRAF; DTX1; HBEGF>"
Lurbinectedin,N,Y,N,,N,2020.0,N,DB12674,L01XX69,CHEMBL4297516,Metastatic Small Cell Lung Cancer,,2020-09-17,CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O,784.8880000000003,4.188940000000003,4,14,COc1ccc2[nH]c3c(c2c1)CCNC31CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,<INDICATION=Metastatic Small Cell Lung Cancer> <TARGET=nan>
Mechlorethamine,Y,Y,N,,N,1949.0,N,DB00888,L01AA05,CHEMBL427,"Carcinoma, Bronchogenic; Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Lymphoma, Diffuse; Mycosis Fungoides (MF); Polycythemia Vera (PV); Stage I Mycosis Fungoides; Malignant effusion",MMP2; GSR; GSTP1; CXCR2; NOS1; BAX; ERBB2; MT-CO1; XRCC1; TSHB; CSF2,2024-07-24,CN(CCCl)CCCl,156.056,1.3958,0,1,CN(CCCl)CCCl,"<INDICATION=Carcinoma, Bronchogenic; Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Lymphoma, Diffuse; Mycosis Fungoides (MF); Polycythemia Vera (PV); Stage I Mycosis Fungoides; Malignant effusion> <TARGET=MMP2; GSR; GSTP1; CXCR2; NOS1; BAX; ERBB2; MT-CO1; XRCC1; TSHB; CSF2>"
Medroxyprogesterone,N,Y,Y,,N,1959.0,Y,DB00603,G03DA02; G03AC06; L02AB02,CHEMBL717,Metastatic Renal Cell Carcinoma; Metastatic Endometrial carcinoma,BAX; PGR; VDR; MMP1; CYP1B1; ESR1; CYP3A5,2024-07-24,CC1CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,344.4950000000001,4.084400000000003,1,3,CC(=O)C1(O)CCC2C3CC(C)C4=CC(=O)CCC4(C)C3CCC21C,<INDICATION=Metastatic Renal Cell Carcinoma; Metastatic Endometrial carcinoma> <TARGET=BAX; PGR; VDR; MMP1; CYP1B1; ESR1; CYP3A5>
Megestrol Acetate,N,Y,Y,,N,1971.0,Y,DB00351,G03DB02; G03AC05; L02AB01,CHEMBL1201139,Advanced Breast Cancer; Advanced Endometrial Cancer,ESR1; ABCB1; AR; PGR; IL2RA; KLK3; NPSR1; IL15; NFE2L2,2024-07-25,CC1=CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,384.5160000000002,4.575300000000004,0,4,CC(=O)OC1(C(C)=O)CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC21C,<INDICATION=Advanced Breast Cancer; Advanced Endometrial Cancer> <TARGET=ESR1; ABCB1; AR; PGR; IL2RA; KLK3; NPSR1; IL15; NFE2L2>
Melphalan,N,Y,Y,,Y,1964.0,Y,DB01042,L01AA03,CHEMBL852,Multiple Myeloma (MM); Ovarian Epithelial Cancer; Severe Hodgkin Lymphoma,CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53,2024-07-25,C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl,305.2049999999999,1.925,2,3,NC(Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,<INDICATION=Multiple Myeloma (MM); Ovarian Epithelial Cancer; Severe Hodgkin Lymphoma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan Flufenamide,Y,Y,N,,N,2021.0,N,DB16627,L01AA10,CHEMBL4303060,Relapsed Or Refractory Multiple Myeloma,CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53,2024-07-24,CCOC(=O)C(CC1=CC=C(C=C1)F)NC(=O)C(CC2=CC=C(C=C2)N(CCCl)CCCl)N,498.4260000000003,3.270100000000001,2,5,CCOC(=O)C(Cc1ccc(F)cc1)NC(=O)C(N)Cc1ccc(N(CCCl)CCCl)cc1,<INDICATION=Relapsed Or Refractory Multiple Myeloma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Mercaptopurine,Y,Y,N,,Y,1953.0,Y,DB01033,L01BB02,CHEMBL1425,"Acute Lymphoblastic Leukaemias (ALL); Acute Promyelocytic Leukemia (APL); Lymphoma, Lymphoblastic",IDH1; KDM4A; BAZ2B,2024-07-24,C1=NC2=C(N1)C(=S)N=CN2,152.18200000000002,1.0154899999999998,2,3,S=c1nc[nH]c2nc[nH]c12,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Promyelocytic Leukemia (APL); Lymphoma, Lymphoblastic> <TARGET=IDH1; KDM4A; BAZ2B>"
Methotrexate,Y,Y,N,,Y,1953.0,Y,DB00563,L04AX03; L01BA01,CHEMBL34259,"Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer",TYMS; CPT1A; MIR4268; NFATC2; SPECC1L; CDH16; POLB; TNFAIP3; CCND1; GSTM1; ERCC2; NTRK3; GSTT1; ENG; IKZF1; MSH3; CLTC; S100A12; NR1I2; VDR; S100A8; AFP; NQO1; NCOA3; KCNA1; IMPDH1; ADA; HGF; PPARG; NOP2; POLH; NTRK1; GLS; KLRD1; NALCN; FOLH1; CYP2C19; APEX1; CYP2C9; FTCDNL1; DOK5; GATA3; NOS3; PNPLA3; TP53; TLR4; ALOX5; FGFR4; SULT2A1; SLC29A1; HSPB2; SOD2; FLT3; ENOSF1; ICAM3; GSK3B; IDH1; LINC00251; IGHMBP2; SLC22A11; POLI; BIRC5; CYP1A2; FCGR3B; ATF5; SLC28A3; FGF14; HLA-E; BAX; ATP5F1E; KIR2DS4; SLC46A1; BCOR; TARDBP; CDK9; EHMT2; RBMS3; FOLR1; CYP2B6; COL18A1; PYGL; SLAMF1; E2F1; NR3C1; PFDN4; AHRR; KLC3; HSD17B10; MIR3117; SLCO1B1; ATIC; CDH2; CDKN1B; BMP7; CYP2D6; NFATC1; SLC22A8; TAT; DHFR; SLC22A9; ABCC4; FOXP3; CYP3A4; TPM3; ALK; IL2; HLA-C; NFE2L2; SLC16A7; IL1RN; SLC19A1; MPHOSPH8,2024-07-25,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,454.44700000000023,0.2684000000000003,5,10,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer> <TARGET=TYMS; CPT1A; MIR4268; NFATC2; SPECC1L; CDH16; POLB; TNFAIP3; CCND1; GSTM1; ERCC2; NTRK3; GSTT1; ENG; IKZF1; MSH3; CLTC; S100A12; NR1I2; VDR; S100A8; AFP; NQO1; NCOA3; KCNA1; IMPDH1; ADA; HGF; PPARG; NOP2; POLH; NTRK1; GLS; KLRD1; NALCN; FOLH1; CYP2C19; APEX1; CYP2C9; FTCDNL1; DOK5; GATA3; NOS3; PNPLA3; TP53; TLR4; ALOX5; FGFR4; SULT2A1; SLC29A1; HSPB2; SOD2; FLT3; ENOSF1; ICAM3; GSK3B; IDH1; LINC00251; IGHMBP2; SLC22A11; POLI; BIRC5; CYP1A2; FCGR3B; ATF5; SLC28A3; FGF14; HLA-E; BAX; ATP5F1E; KIR2DS4; SLC46A1; BCOR; TARDBP; CDK9; EHMT2; RBMS3; FOLR1; CYP2B6; COL18A1; PYGL; SLAMF1; E2F1; NR3C1; PFDN4; AHRR; KLC3; HSD17B10; MIR3117; SLCO1B1; ATIC; CDH2; CDKN1B; BMP7; CYP2D6; NFATC1; SLC22A8; TAT; DHFR; SLC22A9; ABCC4; FOXP3; CYP3A4; TPM3; ALK; IL2; HLA-C; NFE2L2; SLC16A7; IL1RN; SLC19A1; MPHOSPH8>"
Midostaurin,Y,Y,N,,N,2017.0,N,DB06595,L01EX10,CHEMBL608533,Acute Myeloid Leukemia (AML); Malignant mast cell neoplasm; Systemic mastocytosis with associated hematological neoplasm,NTRK3; NPM1; PDGFRA; FLT3; STK32B; JAK3; IL6; IDH2; PRKCQ; KDR; PRKCE; DPYS; JAK2; FGFR3; LATS2; PRKCB; CBL; PRKCH; CTSV; PRKCA; PDGFRB; IL2; PIK3CA; PRKD1; FGFR1; JAK1; PRKCI; PIK3CB; TNF; PRKCG; PRKCD; PRKD3; KIT; PRKCZ; HSPA4; YES1,2024-07-24,CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC,570.6490000000003,5.906800000000007,1,6,COC1C(N(C)C(=O)c2ccccc2)CC2OC1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,<INDICATION=Acute Myeloid Leukemia (AML); Malignant mast cell neoplasm; Systemic mastocytosis with associated hematological neoplasm> <TARGET=NTRK3; NPM1; PDGFRA; FLT3; STK32B; JAK3; IL6; IDH2; PRKCQ; KDR; PRKCE; DPYS; JAK2; FGFR3; LATS2; PRKCB; CBL; PRKCH; CTSV; PRKCA; PDGFRB; IL2; PIK3CA; PRKD1; FGFR1; JAK1; PRKCI; PIK3CB; TNF; PRKCG; PRKCD; PRKD3; KIT; PRKCZ; HSPA4; YES1>
Mifamurtide,Y,N,N,,N,2009.0,N,DB13615,L03AX15,CHEMBL2107354,"High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma",NOD2,2024-02-07,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(C(=O)N)NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(=O)C)C(C(CO)O)O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],1277.5150000000006,1.1521999999999886,9,19,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mirvetuximab Soravtansine,Y,Y,N,,N,2022.0,N,DB12489,L01FX26,CHEMBL3545132,"Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer",HOXB2,2024-07-24,CC1C2CC(C(C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)CC(C4(C1O4)C)OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(=O)N)S(=O)(=O)O)C)C)OC)(NC(=O)O2)O,977.618,4.5865000000000045,4,15,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(=O)(=O)O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,"<INDICATION=Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer> <TARGET=HOXB2>"
Mitomycin,N,Y,Y,,N,1981.0,Y,DB00305,L01DC03,CHEMBL105,"Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; Breast Cancer; Cancer, Anal; Cancer, Bladder; Cervical Cancers; Head and Neck Carcinoma; Mesothelioma; Non-Small Cell Lung Carcinoma (NSCLC); Low-grade Upper Tract Urothelial Cancer (LG-UTUC)",IL1A; PALB2; LGALS2; DHFR; XDH; BRCA1; CYP3A4; CYP1A2; TP53; CYP2C19; AR; CGB5; KRT18; TYMS; VWF; CYP7B1; BGLAP; FANCC; ABCB4; CYP2C9; TAT; MAPK10; CYP2D6; ABCB1,2024-07-25,CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N,334.33200000000005,-1.6511999999999976,3,8,COC12C(COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1CC1NC12,"<INDICATION=Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; Breast Cancer; Cancer, Anal; Cancer, Bladder; Cervical Cancers; Head and Neck Carcinoma; Mesothelioma; Non-Small Cell Lung Carcinoma (NSCLC); Low-grade Upper Tract Urothelial Cancer (LG-UTUC)> <TARGET=IL1A; PALB2; LGALS2; DHFR; XDH; BRCA1; CYP3A4; CYP1A2; TP53; CYP2C19; AR; CGB5; KRT18; TYMS; VWF; CYP7B1; BGLAP; FANCC; ABCB4; CYP2C9; TAT; MAPK10; CYP2D6; ABCB1>"
Mitoxantrone,N,Y,Y,,N,1987.0,Y,DB01204,L01DB07,CHEMBL58,"Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma",UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1,2024-07-24,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO,444.4880000000002,-0.1392000000000001,8,10,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma> <TARGET=UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1>"
Mobocertinib,N,Y,N,,N,2021.0,N,DB16390,L01EB10,CHEMBL4650319,"Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer",EGFR,2024-02-07,CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC,585.7090000000003,5.075000000000004,2,10,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Nab-Paclitaxel,Y,Y,N,,N,2005.0,Y,Not found in DrugBank,L01CD01,CHEMBL428647,Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer,TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A,2024-07-24,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,853.9180000000003,3.735700000000004,4,14,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nelarabine,Y,Y,N,,N,2005.0,Y,DB01280,L01BB07,CHEMBL1201112,Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory; Refractory Acute Lymphoblastic Leukemia,POLA1; NT5C2,2024-02-07,COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N,297.2710000000001,-1.9713999999999987,4,10,COc1nc(N)nc2c1ncn2C1OC(CO)C(O)C1O,<INDICATION=Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory; Refractory Acute Lymphoblastic Leukemia> <TARGET=POLA1; NT5C2>
Neratinib,Y,Y,N,,N,2017.0,N,DB11828,L01EH02,CHEMBL180022,Breast Cancer,KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2,2024-07-24,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,557.0540000000001,5.932480000000006,2,8,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Nilotinib,Y,Y,N,,Y,2007.0,N,DB04868,L01EA03,CHEMBL255863,"Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia",DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1,2024-07-24,CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,529.5260000000002,6.355840000000004,2,7,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,"<INDICATION=Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia> <TARGET=DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1>"
Nilutamide,N,Y,N,,N,1996.0,Y,DB00665,L02BB02,CHEMBL1274,Metastatic Hormone Refractory Prostate Cancer,KLK3; AR; CYP2C9; CYP2D6; NFE2L2; CYP2C19; CYP1A2; PRL; BEVI; CYP3A4,2024-07-24,CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C,317.223,2.4484000000000004,1,4,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,<INDICATION=Metastatic Hormone Refractory Prostate Cancer> <TARGET=KLK3; AR; CYP2C9; CYP2D6; NFE2L2; CYP2C19; CYP1A2; PRL; BEVI; CYP3A4>
Nintedanib,Y,Y,N,,N,2014.0,Y,DB09079,L01EX09,CHEMBL502835,Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma,FGFR2; FGFR3; CFLAR; PIK3CA; PDGFRA; FLT1; KIT; KDR; AKT1; DRD1; DPYSL2; CTSV; DPP4; SLC26A3; DRD3; DPYSL3; FLT4; DSP; DR1; FGFR4; FGFR1; PDGFRB; DRD2; DPP6; RET,2024-07-24,CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,539.6360000000003,4.039400000000003,2,7,COC(=O)c1ccc2c(C(=Nc3ccc(N(C)C(=O)CN4CCN(C)CC4)cc3)c3ccccc3)c(O)[nH]c2c1,<INDICATION=Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma> <TARGET=FGFR2; FGFR3; CFLAR; PIK3CA; PDGFRA; FLT1; KIT; KDR; AKT1; DRD1; DPYSL2; CTSV; DPP4; SLC26A3; DRD3; DPYSL3; FLT4; DSP; DR1; FGFR4; FGFR1; PDGFRB; DRD2; DPP6; RET>
Niraparib,Y,Y,N,,N,2017.0,N,DB11793,L01XK02,CHEMBL1094636,Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer,BRCA1; MYCN; BRCA2; PARP1; GNAI2P1; IDH1; PTEN; ARID1A; ATM; GNAI2; CD274; SLFN11; ATR; PARP2,2024-07-24,C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N,320.3960000000001,2.5914,2,4,NC(=O)c1cccc2cn(-c3ccc(C4CCCNC4)cc3)nc12,<INDICATION=Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer> <TARGET=BRCA1; MYCN; BRCA2; PARP1; GNAI2P1; IDH1; PTEN; ARID1A; ATM; GNAI2; CD274; SLFN11; ATR; PARP2>
Nirogacestat Hydrobromide,N,Y,N,,N,2023.0,N,DB12005,L01XX81,CHEMBL4298153,Progressive Desmoid Tumors,PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1,2024-11-28,CCCC(C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)NC2CCC3=C(C2)C(=CC(=C3)F)F.Br.Br,651.4790000000003,5.942200000000007,3,5,Br.Br.CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,<INDICATION=Progressive Desmoid Tumors> <TARGET=PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1>
Olaparib,Y,Y,N,,N,2014.0,N,DB09074,L01XK01,CHEMBL521686,Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer,PPP2R2A; ESR1; PARP1; FFAR1; PGR; BRAF; ESR2; BRCA2; PALB2; STK11; CHEK2; BRCA1; PTEN; DNMT3A; ARID1A; TET2; IDH1; MYC; ATRX; CDK12; TP53; GNAI2P1; IDH2; HDAC2; NRAS; ERBB2; PARP3; PIK3CA; VHL; ATR; KDM6A; MYCN; BAP1; FANCA; FLT3; SF3B1; RAD54L; BARD1; CHEK1; JAK2; GNAI2; PARP2; ATM; MSH3,2024-07-24,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,434.4710000000001,2.3473999999999995,1,4,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,<INDICATION=Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer> <TARGET=PPP2R2A; ESR1; PARP1; FFAR1; PGR; BRAF; ESR2; BRCA2; PALB2; STK11; CHEK2; BRCA1; PTEN; DNMT3A; ARID1A; TET2; IDH1; MYC; ATRX; CDK12; TP53; GNAI2P1; IDH2; HDAC2; NRAS; ERBB2; PARP3; PIK3CA; VHL; ATR; KDM6A; MYCN; BAP1; FANCA; FLT3; SF3B1; RAD54L; BARD1; CHEK1; JAK2; GNAI2; PARP2; ATM; MSH3>
Olutasidenib,N,Y,N,,N,2022.0,N,DB16267,,CHEMBL4297610,"Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)",IDH1; GPX1P2,2024-07-24,CC(C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N,354.79700000000014,2.9249800000000006,2,5,CC(Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O,"<INDICATION=Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH1; GPX1P2>"
Omacetaxine Mepesuccinate,N,Y,N,,N,2009.0,N,DB04865,L01XX40,CHEMBL46286,"Refractory, accelerated phase Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia",BIRC5; FLT3; TERT; BCR; ABL1,2024-07-24,CC(C)(CCCC(CC(=O)OC)(C(=O)OC1C2C3=CC4=C(C=C3CCN5C2(CCC5)C=C1OC)OCO4)O)O,545.6290000000006,2.580700000000002,2,10,COC(=O)CC(O)(CCCC(C)(C)O)C(=O)OC1C(OC)=CC23CCCN2CCc2cc4c(cc2C13)OCO4,"<INDICATION=Refractory, accelerated phase Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia> <TARGET=BIRC5; FLT3; TERT; BCR; ABL1>"
Osimertinib,Y,Y,N,,N,2015.0,N,DB09330,L01EB04,CHEMBL3353410,Metastatic Non-Small Cell Lung Cancer,EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS,2024-07-24,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC,499.6190000000003,4.509800000000004,2,8,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS>
Oxaliplatin,N,Y,Y,,Y,2002.0,Y,DB00526,L01XA03,CHEMBL414804,Advanced Colorectal Cancer; Advanced Ovarian Cancer; Advanced Pancreatic Cancer; Chronic Lymphocytic Leukemia (CLL) - Refractory; Colon Cancer Stage III; Esophageal Cancers; Malignant Neoplasm of Stomach; Advanced biliary adenocarcinoma; Refractory Neuroendocrine Tumour; Refractory Non-Hodgkin's lymphoma; Refractory Testicular cancer,DPYD; GSTP1; PARD3B; GNA13; BCL2; BRAF; BRCA1; ABCC1; CD274; DKK1; FOXC2; FGFR2; MLH1; CXCL10; ATP7A; KRAS; ABL1; ABCC5; KCNQ1; IGF2BP2; TP53; PIN1; MTHFR; GCKR; PMS2; ZEB1; SELE; MSH2; BAX; XRCC3; MSH6; PTEN; ATM; PTGS2; CSMD1; ATP7B; KLC3; MGAT4A; PIK3CA; MT1A; ABCC2,2024-07-25,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],397.288,1.5551,2,2,O=C(O)C(=O)O.[NH-]C1CCCCC1[NH-].[Pt+2],<INDICATION=Advanced Colorectal Cancer; Advanced Ovarian Cancer; Advanced Pancreatic Cancer; Chronic Lymphocytic Leukemia (CLL) - Refractory; Colon Cancer Stage III; Esophageal Cancers; Malignant Neoplasm of Stomach; Advanced biliary adenocarcinoma; Refractory Neuroendocrine Tumour; Refractory Non-Hodgkin's lymphoma; Refractory Testicular cancer> <TARGET=DPYD; GSTP1; PARD3B; GNA13; BCL2; BRAF; BRCA1; ABCC1; CD274; DKK1; FOXC2; FGFR2; MLH1; CXCL10; ATP7A; KRAS; ABL1; ABCC5; KCNQ1; IGF2BP2; TP53; PIN1; MTHFR; GCKR; PMS2; ZEB1; SELE; MSH2; BAX; XRCC3; MSH6; PTEN; ATM; PTGS2; CSMD1; ATP7B; KLC3; MGAT4A; PIK3CA; MT1A; ABCC2>
Paclitaxel,Y,Y,N,,Y,1992.0,Y,DB01229,L01CD01,CHEMBL428647,Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer,TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A,2024-07-24,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,853.9180000000003,3.735700000000004,4,14,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Padeliporfin,Y,N,N,,N,2017.0,N,DB15575,L01XD07,CHEMBL4298112,Low-Risk Prostate Cancer of the one lobe only,,2020-09-17,CCC1C(C2=CC3=NC(=C(C3=C(C)[O-])C)C=C4C(C(C(=N4)C(=C5C(=C(C(=N5)C=C1N2)C)C(=NCCS(=O)(=O)O)[O-])CC(=O)OC)CCC(=O)O)C)C.[Pd+2],840.2640000000001,3.0842000000000027,3,12,CCC1C2=CC3=NC(=C(CC(=O)OC)C4=NC(=CC5=C(C)C(=C(C)[O-])C(=N5)C=C(N2)C1C)C(C)C4CCC(=O)O)C(C([O-])=NCCS(=O)(=O)O)=C3C.[Pd+2],<INDICATION=Low-Risk Prostate Cancer of the one lobe only> <TARGET=nan>
Palbociclib,Y,Y,N,,N,2015.0,N,DB09073,L01EF01,CHEMBL189963,"Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer",MAP4K4; ESR1; CHEK1; LRRK2; CLK2; PIK3CA; CCND2; CCND1; CDK4; MAPK8; PRKAA1; DYRK1B; ERBB2; BRAF; CCND3; TP53; SMARCA4; CDK5; CDK9; CDK6; PGR; CLK4; TAOK1; RB1; PRKD3; CDKN2A; CDKN2B; DAPK3; MAP4K5; DYRK1A; ESR2; KRAS; ROCK2; ALK; MET; PAK4; RPS6KA3; MAPK9; CCNE2; RET; NEK2; NRAS; MAP4K2; CCNE1; EIF4EBP1; PRKX; PTEN; MST1R; FLT3,2024-07-24,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,447.5430000000004,2.965820000000001,2,9,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,"<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=MAP4K4; ESR1; CHEK1; LRRK2; CLK2; PIK3CA; CCND2; CCND1; CDK4; MAPK8; PRKAA1; DYRK1B; ERBB2; BRAF; CCND3; TP53; SMARCA4; CDK5; CDK9; CDK6; PGR; CLK4; TAOK1; RB1; PRKD3; CDKN2A; CDKN2B; DAPK3; MAP4K5; DYRK1A; ESR2; KRAS; ROCK2; ALK; MET; PAK4; RPS6KA3; MAPK9; CCNE2; RET; NEK2; NRAS; MAP4K2; CCNE1; EIF4EBP1; PRKX; PTEN; MST1R; FLT3>"
Panobinostat,Y,Y,N,,N,2015.0,N,DB06603,L01XH03,CHEMBL483254,Refractory Multiple Myeloma,HDAC1; GDF2; HDAC3; SIRT3; SMARCB1; SIRT1; HDAC2; HDAC8; HDAC9; HDAC4; BRAF; SIRT4; GAPDHP1; MYCN; HDAC10; SIRT2; SIRT5; GARS1; HDAC6; BAP1; CSF1R; HDAC7; SIRT7; ACTL6A; HDAC11; GAS1; HDAC5; SIRT6; GDF9; IDH1; GART; GAS2; KMT2A,2024-07-24,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO,349.43399999999997,3.3272200000000014,4,3,Cc1[nH]c2ccccc2c1CCNCc1ccc(C=CC(=O)NO)cc1,<INDICATION=Refractory Multiple Myeloma> <TARGET=HDAC1; GDF2; HDAC3; SIRT3; SMARCB1; SIRT1; HDAC2; HDAC8; HDAC9; HDAC4; BRAF; SIRT4; GAPDHP1; MYCN; HDAC10; SIRT2; SIRT5; GARS1; HDAC6; BAP1; CSF1R; HDAC7; SIRT7; ACTL6A; HDAC11; GAS1; HDAC5; SIRT6; GDF9; IDH1; GART; GAS2; KMT2A>
Pazopanib,Y,Y,N,,N,2009.0,Y,DB06589,L01EX03,CHEMBL477772,Advanced Renal Cell Carcinoma; Advanced Soft Tissue Sarcoma; Advanced Thyroid cancer,VHL; KDR; DPYSL2; FGFR1; FGFR2; FLT4; KIT; HFE; PDGFRB; NEK2; HIF1A; TP53; DRD3; ALK; CSF1R; VEGFA; NR1I2; DPYD; NRAS; CDK7; MTOR; LIMK1; ABL1; PDGFRA; AURKA; MAPK9; LCK; DRD2; ITK; MAPK8; UGT1A1; NF1; RET; DRD1; CYP3A4; PBRM1; DPT; AURKB; LTK; MAP4K4; HLA-B; HDAC2; PPARD; TAOK1; DPP6; EWSR1; AR; CYP2C8; PTK2; FYN; SCGB3A1; CXCL8; IGF1R; FLT1; MET; FGFR3; YES1; TNK2,2024-07-25,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,437.52900000000017,3.1390399999999996,2,8,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,<INDICATION=Advanced Renal Cell Carcinoma; Advanced Soft Tissue Sarcoma; Advanced Thyroid cancer> <TARGET=VHL; KDR; DPYSL2; FGFR1; FGFR2; FLT4; KIT; HFE; PDGFRB; NEK2; HIF1A; TP53; DRD3; ALK; CSF1R; VEGFA; NR1I2; DPYD; NRAS; CDK7; MTOR; LIMK1; ABL1; PDGFRA; AURKA; MAPK9; LCK; DRD2; ITK; MAPK8; UGT1A1; NF1; RET; DRD1; CYP3A4; PBRM1; DPT; AURKB; LTK; MAP4K4; HLA-B; HDAC2; PPARD; TAOK1; DPP6; EWSR1; AR; CYP2C8; PTK2; FYN; SCGB3A1; CXCL8; IGF1R; FLT1; MET; FGFR3; YES1; TNK2>
Pemetrexed,Y,Y,N,,N,2004.0,Y,DB00642,L01BA04,CHEMBL225072,"Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma",RRM1; CAMKK2; DHFR; EGFR; ALK; TYMS; VEGFA; SLC22A8; ATIC; SLC46A1; GCGR; ROS1; MTHFR; CD274; GART; KRAS; FOLR3; GGH; EXO1; PTEN; MTHFD1; XRCC1; ABCC2; ERCC2; SLC19A1,2024-07-25,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,427.4170000000002,0.6664,6,6,Nc1nc2[nH]cc(CCc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,"<INDICATION=Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma> <TARGET=RRM1; CAMKK2; DHFR; EGFR; ALK; TYMS; VEGFA; SLC22A8; ATIC; SLC46A1; GCGR; ROS1; MTHFR; CD274; GART; KRAS; FOLR3; GGH; EXO1; PTEN; MTHFD1; XRCC1; ABCC2; ERCC2; SLC19A1>"
Pemigatinib,Y,Y,N,,N,2020.0,N,DB15102,L01EN02,CHEMBL4297522,"Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas",FGFR3; FGFR2; DPYSL3; DR1; DPYSL2; FGFR1,2024-07-24,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,487.5070000000003,3.657000000000002,1,6,CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR3; FGFR2; DPYSL3; DR1; DPYSL2; FGFR1>"
Pentostatin,N,N,Y,,N,1991.0,Y,DB00552,L01XX08,CHEMBL1580,"B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory; Chronic Lymphocytic Leukaemia (CLL); Hairy Cell Leukemia (HCL); Mycosis Fungoides (MF); Sezary Syndrome",CCR1; PRKAA1; ADA,2024-07-24,C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O,268.273,-0.9890000000000004,4,8,OCC1OC(n2cnc3c2NC=NCC3O)CC1O,"<INDICATION=B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory; Chronic Lymphocytic Leukaemia (CLL); Hairy Cell Leukemia (HCL); Mycosis Fungoides (MF); Sezary Syndrome> <TARGET=CCR1; PRKAA1; ADA>"
Pipobroman,N,N,Y,,N,1966.0,,DB00236,L01AX02,CHEMBL1585,,NFE2L2; KDM4E; ALDH1A1,2024-07-24,C1CN(CCN1C(=O)CCBr)C(=O)CCBr,356.05800000000005,1.2272,0,2,O=C(CCBr)N1CCN(C(=O)CCBr)CC1,<INDICATION=nan> <TARGET=NFE2L2; KDM4E; ALDH1A1>
Pirarubicin,N,N,N,Japan,N,,,DB11616,L01DB08,CHEMBL2354444,,ABCC1; KMT2A; POLK; MYCN; FEN1; TP53; GLS; HTT; USP1,2024-07-24,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OC6CCCCO6,627.643,1.5521999999999991,5,13,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(OC2CCCCO2)C(C)O1,<INDICATION=nan> <TARGET=ABCC1; KMT2A; POLK; MYCN; FEN1; TP53; GLS; HTT; USP1>
Pirtobrutinib,Y,Y,N,,N,2023.0,N,DB17472,L01EL05,CHEMBL4650485,"Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma",BTK; TP53; EFNB2; IGH,2024-07-24,CC(C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N,479.43400000000025,3.432200000000001,3,6,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn(C(C)C(F)(F)F)c(N)c2C(N)=O)cc1,"<INDICATION=Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma> <TARGET=BTK; TP53; EFNB2; IGH>"
Pixantrone,Y,N,N,,N,2012.0,N,DB06193,L01DB11,CHEMBL167731,"Non-Hodgkin's Lymphoma, Relapsed; Refractory Non-Hodgkin's lymphoma",TOP2A,2024-02-07,C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C2=O)C=NC=C3)NCCN,325.37200000000007,0.5982000000000007,4,7,NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,"<INDICATION=Non-Hodgkin's Lymphoma, Relapsed; Refractory Non-Hodgkin's lymphoma> <TARGET=TOP2A>"
Pomalidomide,Y,Y,N,,N,2013.0,Y,DB08910,L04AX06,CHEMBL43452,Refractory Multiple Myeloma,CRBN; RBX1; CUL4A; DDB1,2024-07-24,C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N,273.248,-0.3300000000000004,2,5,Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,<INDICATION=Refractory Multiple Myeloma> <TARGET=CRBN; RBX1; CUL4A; DDB1>
Ponatinib,Y,Y,N,,N,2012.0,N,DB08901,L01EA05,CHEMBL1171837,Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia,FGFR1; ABL1; FLT3; CDK19; FAP; FGFR3; BCR; PDGFRA; ABL2; FGFR2; KRAS; PDGFRB; ABI1; KIT; EIF4EP1; EML4; FANCG; SRC; PTK2B; RIPK2; YES1; FGFR4; BRAF; KDR; RET,2024-07-24,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,532.5700000000003,4.456020000000003,1,6,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,<INDICATION=Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia> <TARGET=FGFR1; ABL1; FLT3; CDK19; FAP; FGFR3; BCR; PDGFRA; ABL2; FGFR2; KRAS; PDGFRB; ABI1; KIT; EIF4EP1; EML4; FANCG; SRC; PTK2B; RIPK2; YES1; FGFR4; BRAF; KDR; RET>
Pralatrexate,Y,Y,N,,N,2009.0,Y,DB06813,L01BA05,CHEMBL1201746,Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified,DHFR; PDF; RFC1,2024-07-24,C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,477.4810000000003,0.9815999999999996,5,9,C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,<INDICATION=Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified> <TARGET=DHFR; PDF; RFC1>
Pralsetinib,Y,Y,N,,N,2020.0,N,DB15822,L01EX23,CHEMBL4297597,Metastatic RET-fusion Non Small Cell Lung Cancer,EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET,2024-07-24,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)NC(C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC,533.6120000000002,4.200140000000003,3,9,COC1(C(=O)NC(C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,<INDICATION=Metastatic RET-fusion Non Small Cell Lung Cancer> <TARGET=EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET>
Prednisolone,Y,Y,N,,Y,1955.0,Y,DB00860,S03BA02; S02BA03; S01CB02; S01BA04; R01AD02; H02AB06; D07XA02; D07AA03; C05AA04; A07EA01,CHEMBL131,"Hypercalcemia of Malignancy; Leukemia, Acute; Malignant Lymphomas; Mycosis Fungoides (MF)",LCAT; PNPLA3; CYP3A4; ALPP; NR3C1; DSE; NFE2L2; FCGR3A; FCGR3B; CYBA; MTHFR; TSPYL1; GATA3; AR; RAC2; NR3C2; CYP3A5; BDM; TAT; G6PD; HMGB1; BGLAP; RPS19; CD34; PLG; TG; ANXA1; BAX,2024-07-25,CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O,360.4500000000001,1.5576,3,5,CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,"<INDICATION=Hypercalcemia of Malignancy; Leukemia, Acute; Malignant Lymphomas; Mycosis Fungoides (MF)> <TARGET=LCAT; PNPLA3; CYP3A4; ALPP; NR3C1; DSE; NFE2L2; FCGR3A; FCGR3B; CYBA; MTHFR; TSPYL1; GATA3; AR; RAC2; NR3C2; CYP3A5; BDM; TAT; G6PD; HMGB1; BGLAP; RPS19; CD34; PLG; TG; ANXA1; BAX>"
Prednisone,N,Y,Y,,N,1955.0,Y,DB00635,H02AB07; A07EA03,CHEMBL635,"Acute Lymphoblastic Leukaemias (ALL); Aggressive Lymphoma; Hypercalcemia of Malignancy; Leukemia, Acute; Leukemias; Malignant Lymphomas; Metastatic Castration Resistant Prostate Cancer; Mycosis Fungoides (MF)",BMP7; TYMS; GSTM1; GSTP1; MIR4268; MC2R; NOS3; DOK5; ITGB2; TG; CXCL12; CYP3A5; CALCA; CYP3A4; VWF; MIR3117; CYP2C9; SLC19A1; TYMSOS; GSTA1; TPMT; IFNG; CYP1A2; GATA3; PTPRC; APOE; LINC00251; NCF4; AR; MYC; MBP; HSD17B10; NR3C1; NFATC1; CTLA4; CYBA; EDNRA; ABCB1; ATF5; BDM; ANXA1; CYP2D6; CYP2C19,2024-07-25,CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C,358.434,1.7658,2,5,CC12C=CC(=O)C=C1CCC1C2C(=O)CC2(C)C1CCC2(O)C(=O)CO,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Aggressive Lymphoma; Hypercalcemia of Malignancy; Leukemia, Acute; Leukemias; Malignant Lymphomas; Metastatic Castration Resistant Prostate Cancer; Mycosis Fungoides (MF)> <TARGET=BMP7; TYMS; GSTM1; GSTP1; MIR4268; MC2R; NOS3; DOK5; ITGB2; TG; CXCL12; CYP3A5; CALCA; CYP3A4; VWF; MIR3117; CYP2C9; SLC19A1; TYMSOS; GSTA1; TPMT; IFNG; CYP1A2; GATA3; PTPRC; APOE; LINC00251; NCF4; AR; MYC; MBP; HSD17B10; NR3C1; NFATC1; CTLA4; CYBA; EDNRA; ABCB1; ATF5; BDM; ANXA1; CYP2D6; CYP2C19>"
Procarbazine,N,Y,Y,,Y,1969.0,N,DB01168,L01XB01,CHEMBL1321,Non-Hodgkin's Lymphoma (NHL); Oligodendrogliomas; Primary Central Nervous System Lymphoma (PCNSL); Stage III Hodgkin's Disease; Stage IV Hodgkin's Disease,CYP1A2; BAX; EPM2AIP1; CSF2; ALOX15,2024-07-24,CC(C)NC(=O)C1=CC=C(C=C1)CNNC,221.304,1.0488,3,3,CNNCc1ccc(C(=O)NC(C)C)cc1,<INDICATION=Non-Hodgkin's Lymphoma (NHL); Oligodendrogliomas; Primary Central Nervous System Lymphoma (PCNSL); Stage III Hodgkin's Disease; Stage IV Hodgkin's Disease> <TARGET=CYP1A2; BAX; EPM2AIP1; CSF2; ALOX15>
Quizartinib,Y,Y,N,,N,2023.0,N,DB12874,L01EX11,CHEMBL576982,Newly Diagnosed Acute Myeloid Leukemia (AML),DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2,2024-07-24,CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3,560.6800000000003,5.856500000000006,2,9,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,<INDICATION=Newly Diagnosed Acute Myeloid Leukemia (AML)> <TARGET=DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2>
Raltitrexed,N,N,Y,Canada,N,1996.0,N,DB00293,L01BA03,CHEMBL225071,Advanced Colorectal Cancer; Pleural Mesotheliomas,CDK2; TYMS; CDKN1B; SLC19A1; ALB; GCGR; DHFR,2024-07-24,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,458.4960000000002,1.9772199999999995,4,7,Cc1nc2ccc(CN(C)c3ccc(C(=O)NC(CCC(=O)O)C(=O)O)s3)cc2c(=O)[nH]1,<INDICATION=Advanced Colorectal Cancer; Pleural Mesotheliomas> <TARGET=CDK2; TYMS; CDKN1B; SLC19A1; ALB; GCGR; DHFR>
Ranimustine,N,N,N,Japan,N,,,DB13832,L01AD07,CHEMBL2105348,,,2020-09-22,COC1C(C(C(C(O1)CNC(=O)N(CCCl)N=O)O)O)O,327.721,-1.6277999999999992,4,8,COC1OC(CNC(=O)N(CCCl)N=O)C(O)C(O)C1O,<INDICATION=nan> <TARGET=nan>
Regorafenib,Y,Y,N,,N,2012.0,N,DB08896,L01EX05,CHEMBL1946170,Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor,PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4,2024-07-24,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,482.8210000000001,5.688800000000001,3,4,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,<INDICATION=Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4>
Relugolix,Y,Y,N,,N,2020.0,N,DB11853,L02BX04,CHEMBL1800159,Advanced Prostate Cancer,GNRHR; LHCGR,2024-02-07,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,623.6420000000002,3.7505000000000015,2,11,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; LHCGR>
Repotrectinib,N,Y,N,,N,2023.0,N,DB16826,L01EX28,CHEMBL4298138,locally active or metastatic non-small cell lung cancer,EML4; NTRK3; ALK; ROS1; DTX1; NTRK1; DRG2; EPHB2; DRD5P2; HBEGF; DRD5P1,2024-07-24,CC1CNC(=O)C2=C3N=C(C=CN3N=C2)NC(C4=C(O1)C=CC(=C4)F)C,355.3730000000001,2.552200000000001,2,6,CC1CNC(=O)c2cnn3ccc(nc23)NC(C)c2cc(F)ccc2O1,<INDICATION=locally active or metastatic non-small cell lung cancer> <TARGET=EML4; NTRK3; ALK; ROS1; DTX1; NTRK1; DRG2; EPHB2; DRD5P2; HBEGF; DRD5P1>
Ribociclib,Y,Y,N,,N,2017.0,N,DB11730,L01EF02,CHEMBL3545110,Advanced Breast Cancer; Metastatic Breast Cancer,CDK4; PIK3CA; PGR; CCND3; ALK; RB1; JAK2; ERBB2; ESR1; NRAS; CCND1; CCND2; SMARCA4; BRAF; CDK6; ESR2; PTEN; CDKN2A,2024-07-24,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,434.5480000000002,2.7964,2,8,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDK4; PIK3CA; PGR; CCND3; ALK; RB1; JAK2; ERBB2; ESR1; NRAS; CCND1; CCND2; SMARCA4; BRAF; CDK6; ESR2; PTEN; CDKN2A>
Ripretinib,Y,Y,N,,N,2020.0,N,DB14840,L01EX19,CHEMBL4216467,Advanced Gastrointestinal Stromal Tumor (GIST),CYP3A4; KIT; PDGFRB; PDGFRA; DPT,2024-07-24,CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC,510.3670000000001,5.670700000000004,3,5,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,<INDICATION=Advanced Gastrointestinal Stromal Tumor (GIST)> <TARGET=CYP3A4; KIT; PDGFRB; PDGFRA; DPT>
Romidepsin,Y,Y,N,,N,2009.0,Y,DB06176,L01XH02,CHEMBL343448,Refractory peripheral cutaneous T-cell lymphoma,BRAF; HDAC1; HDAC10; CDKN2D; HDAC5; GDF2; HDAC4; GAS2; HDAC6; ADAMTSL4-AS1; HDAC2; GDF9; ERBB2; KMT2A; GART; MSTN; GAPDHP1; HDAC8; HDAC9; ABCB1; GAS1; GARS1; CDKN1A; CTAG1B; HDAC3; HDAC11; BIRC5; HDAC7,2024-07-24,CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C,540.7080000000002,1.4296000000000006,4,8,CC=C1NC(=O)C2CSSCCC=CC(CC(=O)NC(C(C)C)C(=O)N2)OC(=O)C(C(C)C)NC1=O,<INDICATION=Refractory peripheral cutaneous T-cell lymphoma> <TARGET=BRAF; HDAC1; HDAC10; CDKN2D; HDAC5; GDF2; HDAC4; GAS2; HDAC6; ADAMTSL4-AS1; HDAC2; GDF9; ERBB2; KMT2A; GART; MSTN; GAPDHP1; HDAC8; HDAC9; ABCB1; GAS1; GARS1; CDKN1A; CTAG1B; HDAC3; HDAC11; BIRC5; HDAC7>
Rucaparib,Y,Y,N,,N,2016.0,N,DB12332,L01XK03,CHEMBL1173055,Advanced Ovarian Cancer,PARP2; PARP1; PRKD2; BRCA1; CDK12; ATM; CDK1; IDH1; PALB2; CYP2D6; NRAS; DYRK1A; ARID1A; CYP1A2; ATR; PIM1; PTEN; YES1; BRCA2; BRAF; PARP3; GNAI2,2024-07-24,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2,323.3709999999999,2.9793000000000003,3,2,CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,<INDICATION=Advanced Ovarian Cancer> <TARGET=PARP2; PARP1; PRKD2; BRCA1; CDK12; ATM; CDK1; IDH1; PALB2; CYP2D6; NRAS; DYRK1A; ARID1A; CYP1A2; ATR; PIM1; PTEN; YES1; BRCA2; BRAF; PARP3; GNAI2>
Ruxolitinib,Y,Y,N,,N,2011.0,N,DB08877,L01EJ01,CHEMBL1789941,Post Polycythemia Vera Myelofibrosis; Refractory Polycythemia vera,JAK2; SH2B3; CSF3R; JAK3; JAK1; PLAUR; VHL; CRLF2; EPHB3; EPHB2; BRAF; CYP3A4; EPHB1; TYK2; IL7R; TP53; FLT3,2024-07-24,C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,306.37300000000005,3.466380000000002,1,5,N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,<INDICATION=Post Polycythemia Vera Myelofibrosis; Refractory Polycythemia vera> <TARGET=JAK2; SH2B3; CSF3R; JAK3; JAK1; PLAUR; VHL; CRLF2; EPHB3; EPHB2; BRAF; CYP3A4; EPHB1; TYK2; IL7R; TP53; FLT3>
Sacituzumab Govitecan,Y,Y,N,,N,2020.0,N,DB12893,L01FX17,CHEMBL3545262,Metastatic Triple-negative Breast Cancer,ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2,2024-07-24,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)CC(C8=O)SCC(C(=O)O)N)C2=NC9=C1C=C(C=C9)O,1601.795,2.5134999999999983,8,31,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Selinexor,Y,Y,N,,N,2019.0,N,DB11942,L01XX66,CHEMBL3545185,Refractory Multiple Myeloma,FLT3; TET2; TP53; XPO1; H2AX,2024-07-24,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,443.311,3.386700000000001,2,7,O=C(C=Cn1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,<INDICATION=Refractory Multiple Myeloma> <TARGET=FLT3; TET2; TP53; XPO1; H2AX>
Selpercatinib,Y,Y,N,,N,2020.0,N,DB15685,L01EX22,CHEMBL4559134,Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer,RET; KIF5B; PTK2B; CCDC6,2024-07-24,CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O,525.6130000000004,3.284380000000002,1,10,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1,<INDICATION=Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer> <TARGET=RET; KIF5B; PTK2B; CCDC6>
Sonidegib,Y,Y,N,,N,2015.0,N,DB09143,L01XJ02,CHEMBL2105737,"Refractory, locally advanced Basal cell carcinoma",PTCH1; SMO; ALOX12; SUFU; FLT3; MYCN,2024-07-24,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,485.50600000000014,5.821520000000004,1,5,Cc1c(C(=O)Nc2ccc(N3CC(C)OC(C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,"<INDICATION=Refractory, locally advanced Basal cell carcinoma> <TARGET=PTCH1; SMO; ALOX12; SUFU; FLT3; MYCN>"
Sorafenib,Y,Y,N,,N,2005.0,Y,DB00398,L01EX02,CHEMBL1336,Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma,DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7,2024-07-24,CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,464.8310000000002,5.549700000000002,3,4,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,<INDICATION=Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma> <TARGET=DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7>
Sotorasib,Y,Y,N,,N,2021.0,N,DB15569,L01XX73,CHEMBL4535757,"Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer",KRAS; HRAS; NRAS,2024-07-24,CC1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C,560.6050000000002,4.4814200000000035,1,8,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)C(C)C1,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; HRAS; NRAS>"
Streptozocin,N,Y,N,,N,2005.0,N,DB00428,L01AD04,CHEMBL1651906,Stage 4 islet cell carcinoma,SI; IGFBP1; DDIT3; S100B; SSTR1; CYP7B1; CSF2; TRPV1; TH; CTSD; PTGER4; HRAS; OGA; TGFB1; THRSP; SULT1A2; CD40; BCL2; ATF2; ADCYAP1; CDKN1B; ACP5; GALP; CYP2D6; VWF; KCNJ11; UCP1; LCAT; HGF; SLC2A4; SLC5A1; RAMP3; KCNA2; MT1H; NTRK1; HP; MMP2; PRKAA1; SLC2A5; SFTPB; SST; PREP; MYO9B; ENO2; PIK3CA; SLC16A3,2024-07-24,CN(C(=O)NC1C(C(C(OC1O)CO)O)O)N=O,265.222,-2.890899999999998,5,8,CN(N=O)C(=O)NC1C(O)OC(CO)C(O)C1O,<INDICATION=Stage 4 islet cell carcinoma> <TARGET=SI; IGFBP1; DDIT3; S100B; SSTR1; CYP7B1; CSF2; TRPV1; TH; CTSD; PTGER4; HRAS; OGA; TGFB1; THRSP; SULT1A2; CD40; BCL2; ATF2; ADCYAP1; CDKN1B; ACP5; GALP; CYP2D6; VWF; KCNJ11; UCP1; LCAT; HGF; SLC2A4; SLC5A1; RAMP3; KCNA2; MT1H; NTRK1; HP; MMP2; PRKAA1; SLC2A5; SFTPB; SST; PREP; MYO9B; ENO2; PIK3CA; SLC16A3>
Sunitinib,Y,Y,N,,N,2006.0,Y,DB01268,L01EX01,CHEMBL535,"Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors",FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1,2024-07-25,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,398.48200000000014,3.3349400000000022,3,3,CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C,"<INDICATION=Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors> <TARGET=FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1>"
Talazoparib,Y,Y,N,,N,2018.0,N,DB11760,L01XK04,CHEMBL3137320,Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer,MYCN; CDK12; MLH1; STK11; BRCA2; FLT3; SLFN11; PARP2; ATRX; GNAI2; ATR; BRAF; GNAI2P1; PSMD4; PARP1; NRAS; ARID1A; IDH1; EGFR; DNMT3A; ERBB2; IDH2; ATM; BRCA1; TET2; PALB2; PTEN,2024-07-24,CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F,380.35800000000006,2.6285000000000007,2,6,Cn1ncnc1C1c2n[nH]c(=O)c3cc(F)cc(c23)NC1c1ccc(F)cc1,<INDICATION=Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer> <TARGET=MYCN; CDK12; MLH1; STK11; BRCA2; FLT3; SLFN11; PARP2; ATRX; GNAI2; ATR; BRAF; GNAI2P1; PSMD4; PARP1; NRAS; ARID1A; IDH1; EGFR; DNMT3A; ERBB2; IDH2; ATM; BRCA1; TET2; PALB2; PTEN>
Tamoxifen,N,Y,Y,,Y,1977.0,Y,DB00675,L02BA01,CHEMBL83,Breast Cancer; Desmoid Tumors; Endometrial Cancer; Invasive Breast Cancer; Invasive Breast Carcinoma; Metastatic Breast Cancer; Ovarian Cancer,AURKA; ESR1; PGR; FMO3; ATXN2; ESR2; HSPB2; COL18A1; VDR; HEXB; PLD1; EHMT2; CYP2C9; MUC16; ERBB2; RRAS2; SLCO1A2; NFE2L2; NCOA3; NF1; TFF3; CYP2B6; CYP2D6; TP53; FMO1; CYP19A1; EDN1; PLD2; PIP; ZNF613; F2; E2F7; BRCA1; LRMDA; NR1I2; BAZ2B; ALDH3B1; CBX1; GGT1; GMNN; CCND1; MYOD1; DHFR; CYP1A2; SLCO2B1; KLK3; PIK3CA; UGT1A4; BCYRN1P2; NCOA1; NRG1; CETP; CYP3A4; ZNF423; CCNA2; TGM2; IGF1R; IDH1; NTRK1; GAPDH; KDM4A; BGLAP; TYMS; F5; TGFB1,2024-07-24,CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3,371.52400000000006,5.996100000000006,0,2,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,<INDICATION=Breast Cancer; Desmoid Tumors; Endometrial Cancer; Invasive Breast Cancer; Invasive Breast Carcinoma; Metastatic Breast Cancer; Ovarian Cancer> <TARGET=AURKA; ESR1; PGR; FMO3; ATXN2; ESR2; HSPB2; COL18A1; VDR; HEXB; PLD1; EHMT2; CYP2C9; MUC16; ERBB2; RRAS2; SLCO1A2; NFE2L2; NCOA3; NF1; TFF3; CYP2B6; CYP2D6; TP53; FMO1; CYP19A1; EDN1; PLD2; PIP; ZNF613; F2; E2F7; BRCA1; LRMDA; NR1I2; BAZ2B; ALDH3B1; CBX1; GGT1; GMNN; CCND1; MYOD1; DHFR; CYP1A2; SLCO2B1; KLK3; PIK3CA; UGT1A4; BCYRN1P2; NCOA1; NRG1; CETP; CYP3A4; ZNF423; CCNA2; TGM2; IGF1R; IDH1; NTRK1; GAPDH; KDM4A; BGLAP; TYMS; F5; TGFB1>
Tazemetostat,N,Y,N,,N,2020.0,N,DB12887,L01XX72,CHEMBL3414621,Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma,SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A,2024-07-24,CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5,572.75,4.734660000000004,2,6,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,<INDICATION=Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma> <TARGET=SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A>
Temoporfin,Y,N,N,,N,2001.0,N,DB11630,L01XD05,CHEMBL500576,Advanced Head and Neck Squamous Cell Carcinoma,,2020-09-17,C1CC2=NC1=C(C3=CC=C(N3)C(=C4C=CC(=N4)C(=C5C=CC(=C2C6=CC(=CC=C6)O)N5)C7=CC(=CC=C7)O)C8=CC(=CC=C8)O)C9=CC(=CC=C9)O,680.7640000000002,9.760799999999994,6,6,Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc(c(-c5cccc(O)c5)c5ccc2[nH]5)CC4)C=C3)c1,<INDICATION=Advanced Head and Neck Squamous Cell Carcinoma> <TARGET=nan>
Temozolomide,Y,Y,N,,N,1999.0,Y,DB00853,L01AX03,CHEMBL810,"Advanced Melanoma; Glioblastomas; Primary Central Nervous System Lymphoma (PCNSL); Refractory Ewing Sarcoma; Refractory Neuroblastoma; Soft Tissue Sarcoma (STS); Advanced Neuroendocrine tumor; Refractory Anaplastic astrocytoma; Refractory, advanced Mycosis fungoides; Refractory, advanced Sezary Syndrome",PIK3CA; MGMT; HDAC4; PTEN; ATRX; TP53; MYC; IDH1; H2AX; BRCA2; GSTP1; CDKN2A; ATR; PRL; MSH6; CSF2; ALK; ARID1A; ATM; SLFN11,2024-07-24,CN1C(=O)N2C=NC(=C2N=N1)C(=O)N,194.15399999999997,-2.0781,1,7,Cn1nnc2c(C(N)=O)ncn2c1=O,"<INDICATION=Advanced Melanoma; Glioblastomas; Primary Central Nervous System Lymphoma (PCNSL); Refractory Ewing Sarcoma; Refractory Neuroblastoma; Soft Tissue Sarcoma (STS); Advanced Neuroendocrine tumor; Refractory Anaplastic astrocytoma; Refractory, advanced Mycosis fungoides; Refractory, advanced Sezary Syndrome> <TARGET=PIK3CA; MGMT; HDAC4; PTEN; ATRX; TP53; MYC; IDH1; H2AX; BRCA2; GSTP1; CDKN2A; ATR; PRL; MSH6; CSF2; ALK; ARID1A; ATM; SLFN11>"
Temsirolimus,Y,Y,N,,N,2007.0,Y,DB06287,L01EG01,CHEMBL1201182,Advanced Renal Cell Carcinoma,NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD,2024-07-24,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,1030.303,5.722400000000007,4,16,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OC(=O)C(C)(CO)CO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD>
Tepotinib,Y,Y,N,,N,2021.0,N,DB15133,L01EX21,CHEMBL3402762,Metastatic Non-Small Cell Lung Cancer,MET; EGFR; DRD4; ALK,2024-07-24,CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N,492.58300000000025,4.007880000000003,0,8,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=MET; EGFR; DRD4; ALK>
Thalidomide,Y,Y,N,,Y,1998.0,N,DB01041,L04AX02,CHEMBL468,Multiple Myeloma (MM); Waldenstrom's Macroglobulinemia (WM); Treatment naive multiple myeloma,FCGR3B; FGFR2; DDB1; CRBN; F2R; RBX1; FCGR3A; TNF; CYP1A2; RPL13; ABCC6; NFKB1; SPG7; XRCC5; ATP7A; CYP4B1; VEGFA; SULT1C4; PTGS2; HLA-B; FGF2; VWF; CUL4A; CHST3; MECOM; NAT2; HGF; ERCC1; CTLA4; SLC10A2; CYP2C19; ITGB2; CTNNB1; IL6R; GSTT1; SNORD68; PPARD,2024-07-24,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,258.233,0.0877999999999994,1,4,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,<INDICATION=Multiple Myeloma (MM); Waldenstrom's Macroglobulinemia (WM); Treatment naive multiple myeloma> <TARGET=FCGR3B; FGFR2; DDB1; CRBN; F2R; RBX1; FCGR3A; TNF; CYP1A2; RPL13; ABCC6; NFKB1; SPG7; XRCC5; ATP7A; CYP4B1; VEGFA; SULT1C4; PTGS2; HLA-B; FGF2; VWF; CUL4A; CHST3; MECOM; NAT2; HGF; ERCC1; CTLA4; SLC10A2; CYP2C19; ITGB2; CTNNB1; IL6R; GSTT1; SNORD68; PPARD>
Thioguanine,N,Y,N,,N,1966.0,N,DB00352,L01BB03,CHEMBL727,Acute Nonlymphocytic Leukemia; Nonlymphocytic Acute myeloid leukemia,KDM4A; CPT1A; GDA; GATA2; LINC00251; GGH; HPGD; IGHMBP2; MGMT; NUDT15; PNPLA3; EHMT2; UGT1A1; NAT1; PAX8; GATA3; BMP7; TPMT; XDH; NFE2L2; IMPDH1; PRPS1; ACHE; IMPDH2; NT5C2; DOK5; MYC; IDH1; HBB; SLC28A3; AR; TPM3; ABCC4,2024-07-24,C1=NC2=C(N1)C(=S)N=C(N2)N,167.197,0.5976899999999998,3,4,Nc1nc(=S)c2[nH]cnc2[nH]1,<INDICATION=Acute Nonlymphocytic Leukemia; Nonlymphocytic Acute myeloid leukemia> <TARGET=KDM4A; CPT1A; GDA; GATA2; LINC00251; GGH; HPGD; IGHMBP2; MGMT; NUDT15; PNPLA3; EHMT2; UGT1A1; NAT1; PAX8; GATA3; BMP7; TPMT; XDH; NFE2L2; IMPDH1; PRPS1; ACHE; IMPDH2; NT5C2; DOK5; MYC; IDH1; HBB; SLC28A3; AR; TPM3; ABCC4>
Thiotepa,Y,Y,N,,N,1959.0,Y,DB04572,L01AC01,CHEMBL671,Adenocarcinoma of the Ovaries; Breast Adenocarcinoma; Papillary transitional cell carcinoma of bladder; Malignant effusion,TP53; HPGD; GMNN; ALDH1A1; CYP2B6; EHMT2; VDR; GSTP1; ALDH3A1; AR,2024-07-24,C1CN1P(=S)(N2CC2)N3CC3,189.22399999999996,0.1576999999999999,0,1,S=P(N1CC1)(N1CC1)N1CC1,<INDICATION=Adenocarcinoma of the Ovaries; Breast Adenocarcinoma; Papillary transitional cell carcinoma of bladder; Malignant effusion> <TARGET=TP53; HPGD; GMNN; ALDH1A1; CYP2B6; EHMT2; VDR; GSTP1; ALDH3A1; AR>
Tivozanib,Y,Y,N,,N,2017.0,N,DB11800,L01EK03,CHEMBL1289494,Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma,FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3,2024-07-24,CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl,454.87000000000023,5.638120000000003,2,7,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,<INDICATION=Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma> <TARGET=FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3>
Topotecan,Y,Y,N,,N,1996.0,Y,DB01030,L01CE01,CHEMBL84,"Acute Myeloid Leukemia (AML); Ewing's Sarcoma; Refractory Neuroblastoma; Metastatic Rhabdomyosarcoma; Recurrent, IV-B Cervical cancer; Refractory CNS lymphoma; Refractory CNS malignancy; Refractory, metastatic Ovarian cancer; Relapsed Small cell lung cancer",DDO; PAX8; IDH1; ABCG2; AR; PLK1; TOP1; ALK; KMT2A; HIF1A; HBB; TSG101; ABCB1; AKT1; TYMS; RB1; TOP1MT; NFE2L2; MDM2; USP1; PTEN; TP53; PIK3CA; BDNF; MUC16,2024-07-24,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,421.45300000000015,1.8467999999999996,2,8,CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,"<INDICATION=Acute Myeloid Leukemia (AML); Ewing's Sarcoma; Refractory Neuroblastoma; Metastatic Rhabdomyosarcoma; Recurrent, IV-B Cervical cancer; Refractory CNS lymphoma; Refractory CNS malignancy; Refractory, metastatic Ovarian cancer; Relapsed Small cell lung cancer> <TARGET=DDO; PAX8; IDH1; ABCG2; AR; PLK1; TOP1; ALK; KMT2A; HIF1A; HBB; TSG101; ABCB1; AKT1; TYMS; RB1; TOP1MT; NFE2L2; MDM2; USP1; PTEN; TP53; PIK3CA; BDNF; MUC16>"
Toremifene,Y,Y,N,,N,1997.0,Y,DB00539,L02BA02,CHEMBL1655,Desmoid Tumors; Metastatic Breast Cancer,CYP1B1; ESR1; ESR2; CYP3A4; TGFB1; HNF4A; AR; CYP2D6; PGR; PLIN1; KDM4A; GMNN; CD80,2024-07-24,CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3,405.9690000000001,6.215000000000006,0,2,CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,<INDICATION=Desmoid Tumors; Metastatic Breast Cancer> <TARGET=CYP1B1; ESR1; ESR2; CYP3A4; TGFB1; HNF4A; AR; CYP2D6; PGR; PLIN1; KDM4A; GMNN; CD80>
Tovorafenib,N,Y,N,,N,2024.0,N,DB15266,,CHEMBL3348923,"Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation",RAF1; BRAF; ARAF; EFNA2; ZHX2,2024-07-24,CC(C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl,506.29700000000014,3.9792000000000014,3,8,CC(NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,"<INDICATION=Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation> <TARGET=RAF1; BRAF; ARAF; EFNA2; ZHX2>"
Trabectedin,Y,Y,N,,N,2015.0,N,DB05109,L01CX01,CHEMBL450449,Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Relapsed platinum-sensitive Ovarian cancer; Unresectable Leiomyosarcoma; Unresectable Liposarcoma,PARP1; TP53; ABCC2; ABCB1; CD274; FGFR2,2024-07-24,CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O,761.8500000000004,3.4132400000000023,4,15,COc1cc2c(cc1O)CCNC21CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,<INDICATION=Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Relapsed platinum-sensitive Ovarian cancer; Unresectable Leiomyosarcoma; Unresectable Liposarcoma> <TARGET=PARP1; TP53; ABCC2; ABCB1; CD274; FGFR2>
Trametinib,Y,Y,N,,N,2013.0,N,DB08911,L01EE01,CHEMBL2103875,Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation,ETV5; BRAF; KRAS; FGFR1; MAP2K1; MAP2K2; TP53; NF1; PRKCH; RAF1; ABL1; ATM; MAP2K5; APC; ERBB3; G6PD; CDKN2A; KEAP1; ARAF; ETV4; RB1; ETV1; MET; VHL; MAP2K6; MAP2K4; DNMT3A; RET; KIT; MDM2; PIK3CA; EML4; PTEN; CD274; ATXN1L; NR2F6; ALK; MAP2K3; CIC; DDX43; RASA1; STK11; FLT3; HRAS; NRAS; CSF3R; CTNNB1; FGFR2; DUSP6; MAP2K7,2024-07-24,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,615.403,3.940120000000002,2,8,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=ETV5; BRAF; KRAS; FGFR1; MAP2K1; MAP2K2; TP53; NF1; PRKCH; RAF1; ABL1; ATM; MAP2K5; APC; ERBB3; G6PD; CDKN2A; KEAP1; ARAF; ETV4; RB1; ETV1; MET; VHL; MAP2K6; MAP2K4; DNMT3A; RET; KIT; MDM2; PIK3CA; EML4; PTEN; CD274; ATXN1L; NR2F6; ALK; MAP2K3; CIC; DDX43; RASA1; STK11; FLT3; HRAS; NRAS; CSF3R; CTNNB1; FGFR2; DUSP6; MAP2K7>
Trastuzumab Emtansine,Y,Y,N,,N,2013.0,N,DB05773,L01FD03,CHEMBL1743082,"Refractory, metastatic Non small cell lung cancer",ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8,2024-07-24,CC1C2CC(C(C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)CC(C4(C1O4)C)OC(=O)C(C)N(C)C(=O)CCSC5CC(=O)N(C5=O)CC6CCC(CC6)C(=O)N)C)C)OC)(NC(=O)O2)O,974.5709999999996,4.057000000000004,3,14,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Tretinoin,N,Y,Y,,N,1971.0,Y,DB00755,D10AD01; L01XF01,CHEMBL38,FAB classification M3 Acute promyelocytic leukemia,SFTPA1; RXRA; EHMT2; TGFBR3; RXRB; TBP; ALDH1A2; RARA; SMARCA4; SMAD2; NR2C1; HIF1A; P2RY2; AMH; SHH; NOS1; CDKN1B; PRL; THBS1; NPM1; TGFB1; TSPYL2; RARG; RET; HES1; MYOD1; BIRC5; IL1R1; BCKDHB; CEACAM1; RAB40B; NRIP1; CXCL8; RB1; XIAP; RARB; RXRG; SPP1; FLT3; MYCN; ERVK2; KLK3; BCHEL1; BCL2L2; BAX; WT1; TG; HOXB1; APOA1; ITGB2; NFE2L2; FAS; MDK; FUS; SLC2A1; PTPRZ1; CD55; TP73; VDR; HAS3; NR2C2; PTCH1; BHLHE40; RPE65; TPO; LIF; DUSP6; BCHE; BCL2; OCLN; CYP2C9; ALPL; KAT2A; HOXD1; IL10; USP1; RARRES1; NR2E1; CYP3A5; GLI1; PML; CALR; MAPK8; MST1; IFNG; EGR2; HSPA8; NR4A1; APOE; BCHEL3; ADH1C,2024-07-25,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,300.44200000000006,5.602600000000005,1,1,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,<INDICATION=FAB classification M3 Acute promyelocytic leukemia> <TARGET=SFTPA1; RXRA; EHMT2; TGFBR3; RXRB; TBP; ALDH1A2; RARA; SMARCA4; SMAD2; NR2C1; HIF1A; P2RY2; AMH; SHH; NOS1; CDKN1B; PRL; THBS1; NPM1; TGFB1; TSPYL2; RARG; RET; HES1; MYOD1; BIRC5; IL1R1; BCKDHB; CEACAM1; RAB40B; NRIP1; CXCL8; RB1; XIAP; RARB; RXRG; SPP1; FLT3; MYCN; ERVK2; KLK3; BCHEL1; BCL2L2; BAX; WT1; TG; HOXB1; APOA1; ITGB2; NFE2L2; FAS; MDK; FUS; SLC2A1; PTPRZ1; CD55; TP73; VDR; HAS3; NR2C2; PTCH1; BHLHE40; RPE65; TPO; LIF; DUSP6; BCHE; BCL2; OCLN; CYP2C9; ALPL; KAT2A; HOXD1; IL10; USP1; RARRES1; NR2E1; CYP3A5; GLI1; PML; CALR; MAPK8; MST1; IFNG; EGR2; HSPA8; NR4A1; APOE; BCHEL3; ADH1C>
Triptorelin,N,Y,Y,,N,2000.0,N,DB06825,L02AE04,CHEMBL1201334,Advanced Prostate Cancer,GNRHR; STS,2024-07-24,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8,1311.4730000000006,-2.294800000000013,17,15,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Trofosfamide,N,N,Y,,N,,,DB12902,L01AA07,CHEMBL462019,Non-Hodgkin's lymphoma,CYP2B6,2024-02-07,C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl,323.58799999999997,2.8352000000000013,0,2,O=P1(N(CCCl)CCCl)OCCCN1CCCl,<INDICATION=Non-Hodgkin's lymphoma> <TARGET=CYP2B6>
Tucatinib,Y,Y,N,,N,2020.0,N,DB11652,L01EH03,CHEMBL3989868,Breast Cancer; Unresectable Breast Cancer,ERBB2; NRAS; HRAS; EN1; EGFR; DXO; KRAS; ERBB4,2024-07-24,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,480.53200000000027,5.093520000000003,2,10,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,<INDICATION=Breast Cancer; Unresectable Breast Cancer> <TARGET=ERBB2; NRAS; HRAS; EN1; EGFR; DXO; KRAS; ERBB4>
Umbralisib,N,Y,N,,N,2021.0,N,DB14989,L01EX25,CHEMBL3948730,B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL),PIK3CD; PIK3CG; ELF2; F7,2024-07-24,CC(C)OC1=C(C=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)C4=C(C(=O)C5=C(O4)C=CC(=C5)F)C6=CC(=CC=C6)F)F,571.5590000000004,6.6627000000000045,1,8,CC(C)Oc1ccc(-c2nn(C(C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,<INDICATION=B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL)> <TARGET=PIK3CD; PIK3CG; ELF2; F7>
Valrubicin,N,Y,N,,N,1998.0,Y,DB00385,L01DB09,CHEMBL1096885,In situ BCG-refractory Bladder carcinoma,TOP2A; AR,2024-02-07,CCCCC(=O)OCC(=O)C1(CC(C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)OC5CC(C(C(O5)C)O)NC(=O)C(F)(F)F)O,723.6500000000005,2.462200000000001,5,13,CCCCC(=O)OCC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C1)C(=O)c1c(OC)cccc1C3=O,<INDICATION=In situ BCG-refractory Bladder carcinoma> <TARGET=TOP2A; AR>
Vandetanib,Y,Y,N,,N,2011.0,N,DB05294,L01EX04,CHEMBL24828,Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer,KDR; RET; PTEN; EGFR; LRRK2; ERBB4; FLT4; FLT1; ALK; FYN; MAP4K5; PDGFRB; GMNN; LCK; KRAS; EPHA1; SRC; EPHB1; EPHA3; TYRO3; AURKB; EPHB4; EPHB3; EPHA10; MAP2K2; IDH1; DRD2; BTK; ABL1; MAP2K1; PTK6; EPHB6; EPHA2; HTT; AXL; FGFR1; CYP3A4; APC; ROCK2; EPHB2; EPHA5; PTK2B; EPHA4; YES1; ERBB2; PDGFRA; DXO; TEK; MTOR; ERBB3; MAPK14; MAP4K4; ATM; LTK; EPHA6; EPHA7; ACVR1; EPHA8,2024-07-24,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,475.3620000000001,5.004200000000004,1,6,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,<INDICATION=Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer> <TARGET=KDR; RET; PTEN; EGFR; LRRK2; ERBB4; FLT4; FLT1; ALK; FYN; MAP4K5; PDGFRB; GMNN; LCK; KRAS; EPHA1; SRC; EPHB1; EPHA3; TYRO3; AURKB; EPHB4; EPHB3; EPHA10; MAP2K2; IDH1; DRD2; BTK; ABL1; MAP2K1; PTK6; EPHB6; EPHA2; HTT; AXL; FGFR1; CYP3A4; APC; ROCK2; EPHB2; EPHA5; PTK2B; EPHA4; YES1; ERBB2; PDGFRA; DXO; TEK; MTOR; ERBB3; MAPK14; MAP4K4; ATM; LTK; EPHA6; EPHA7; ACVR1; EPHA8>
Vemurafenib,Y,Y,N,,N,2011.0,N,DB08881,L01EC01,CHEMBL1229517,Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer,CDKN2A; NRAS; PIK3CA; MITF; PTEN; RB1; MET; PIK3R2; RAC1; BRAF; PREX2; HRAS; NF1; CYP3A4; TET2; MAP2K1; ATXN1L; EFNA2; TP53; KEAP1; CBL; CIC; FGFR2; KRAS; ABCB1; STAG3; YES1; FAH; MAP2K2; CYP1A2; CYP3A; TF; STAG2; SOX10; AKT1; AKT3,2024-07-24,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,489.9310000000001,5.544200000000003,2,4,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer> <TARGET=CDKN2A; NRAS; PIK3CA; MITF; PTEN; RB1; MET; PIK3R2; RAC1; BRAF; PREX2; HRAS; NF1; CYP3A4; TET2; MAP2K1; ATXN1L; EFNA2; TP53; KEAP1; CBL; CIC; FGFR2; KRAS; ABCB1; STAG3; YES1; FAH; MAP2K2; CYP1A2; CYP3A; TF; STAG2; SOX10; AKT1; AKT3>
Venetoclax,Y,Y,N,,N,2016.0,N,DB11581,L01XX52,CHEMBL3137309,Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma,IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1,2024-07-24,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,868.4569999999998,8.659900000000006,3,11,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma> <TARGET=IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1>
Vinblastine,N,Y,Y,,Y,1965.0,Y,DB00570,L01CA01,CHEMBL159,"Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer",TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1,2024-07-24,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,810.9890000000001,3.990900000000004,3,12,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,"<INDICATION=Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer> <TARGET=TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1>"
Vincristine,N,Y,Y,,Y,1965.0,Y,DB00541,L01CA02,CHEMBL90555,"Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma",NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA,2024-07-24,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,824.9720000000002,3.517500000000003,3,12,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C=O)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,"<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma> <TARGET=NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA>"
Vindesine,N,N,Y,,N,1979.0,N,DB00309,L01CA03,CHEMBL238071,"Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant",TUBB; ABCB1; TUBB1; CYP3A4,2024-07-24,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O,753.9410000000001,2.7324000000000033,5,10,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(N)=O)C(O)C5(CC)C=CCN6CCC43C65)C2)C1,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant> <TARGET=TUBB; ABCB1; TUBB1; CYP3A4>"
Vinflunine,Y,N,N,,N,2009.0,N,DB11641,L01CA05,CHEMBL2110725,Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract,TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B,2024-07-24,CCC12C=CCN3C1C4(CC3)C(C(C2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)C6(CC7CC(CN(C7)CC8=C6NC9=CC=CC=C89)C(C)(F)F)C(=O)OC)OC)C,816.9430000000001,5.078700000000005,2,11,CCC12C=CCN3CCC4(c5cc(C6(C(=O)OC)CC7CC(C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)C4C(O)(C(=O)OC)C1OC(C)=O)C32,<INDICATION=Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract> <TARGET=TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B>
Vinorelbine,N,Y,Y,,Y,1994.0,Y,DB00361,L01CA04,CHEMBL553025,"Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer",TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8,2024-07-24,CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,778.9470000000002,4.753600000000004,2,11,CCC1=CC2CN(C1)Cc1c([nH]c3ccccc13)C(C(=O)OC)(c1cc3c(cc1OC)N(C)C1C(O)(C(=O)OC)C(OC(C)=O)C4(CC)C=CCN5CCC31C54)C2,"<INDICATION=Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer> <TARGET=TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8>"
Vismodegib,Y,Y,N,,N,2012.0,N,DB08828,L01XJ01,CHEMBL473417,Locally Advanced Basal Cell Carcinoma; Metastatic Basal cell carcinoma,SMO; PTCH1; SHH; ALOX12,2024-07-24,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,421.30500000000006,4.711200000000003,1,4,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,<INDICATION=Locally Advanced Basal Cell Carcinoma; Metastatic Basal cell carcinoma> <TARGET=SMO; PTCH1; SHH; ALOX12>
Vorasidenib,N,Y,N,,N,2024.0,,DB17097,L01XM04,CHEMBL4279047,Grade 2 astrocytoma or oligodendroglioma,IDH1; IDH2; GRB2; GPX1P2,2024-11-28,CC(C(F)(F)F)NC1=NC(=NC(=N1)C2=NC(=CC=C2)Cl)NC(C)C(F)(F)F,414.741,4.312400000000001,2,6,CC(Nc1nc(NC(C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F,<INDICATION=Grade 2 astrocytoma or oligodendroglioma> <TARGET=IDH1; IDH2; GRB2; GPX1P2>
Vorinostat,N,Y,N,,N,2006.0,N,DB02546,L01XH01,CHEMBL98,Persistent Cutaneous T-Cell Lymphoma; Progressive Cutaneous T-cell lymphoma; Recurrent Cutaneous T-cell lymphoma,TUBA1C; TUBA3D; IDH1; PAX8; TUBB4A; TUBB4B; GAS1; GAPDHP1; HDAC9; TUBB2A; TUBB8; HDAC6; BRAF; NR0B1; HDAC7; HDAC2; GART; HDAC8; GAPDHL17; HDAC11; HDAC4; GAS2; HDAC5; BIRC5; HDAC1; CFTR; TUBA3C; HDAC3; GDF2; GARS1; MYC; TP53; TUBA1A; TUBA3E; CHD4; MSTN; TUBB2B; UGT2B17; TUBA1B; TUBB6; TUBB1; LRRC32; BAP1; GMNN; TUBB3; ERBB2; FBXW7; NFE2L2; ACE; GNA11; HDAC10; TUBB; PTEN; RB1; TUBA4A,2024-07-24,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,264.3249999999999,2.4710999999999994,3,3,O=C(CCCCCCC(=O)Nc1ccccc1)NO,<INDICATION=Persistent Cutaneous T-Cell Lymphoma; Progressive Cutaneous T-cell lymphoma; Recurrent Cutaneous T-cell lymphoma> <TARGET=TUBA1C; TUBA3D; IDH1; PAX8; TUBB4A; TUBB4B; GAS1; GAPDHP1; HDAC9; TUBB2A; TUBB8; HDAC6; BRAF; NR0B1; HDAC7; HDAC2; GART; HDAC8; GAPDHL17; HDAC11; HDAC4; GAS2; HDAC5; BIRC5; HDAC1; CFTR; TUBA3C; HDAC3; GDF2; GARS1; MYC; TP53; TUBA1A; TUBA3E; CHD4; MSTN; TUBB2B; UGT2B17; TUBA1B; TUBB6; TUBB1; LRRC32; BAP1; GMNN; TUBB3; ERBB2; FBXW7; NFE2L2; ACE; GNA11; HDAC10; TUBB; PTEN; RB1; TUBA4A>
Zanubrutinib,Y,Y,N,,N,2019.0,N,DB15035,L01EL03,CHEMBL3936761,Mantle Cell Lymphoma (MCL),TP53; BTK; EFNB2; MYD88,2024-07-24,C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N,471.5610000000002,4.222600000000002,2,6,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,<INDICATION=Mantle Cell Lymphoma (MCL)> <TARGET=TP53; BTK; EFNB2; MYD88>
